

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Appeal Brief Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: September 13, 2005

Signature:

Stacey L. Myers
(Stacey L. Myers)

Docket No.: 381092000720
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES**

In re Application of:

Terrance P. SNUTCH et al.

Application No.: 09/346,794

Filed: July 2, 1999

For: NOVEL HUMAN CALCIUM CHANNELS
AND RELATED PROBES, CELL LINES AND
METHODS

Confirmation No.: 2888

Art Unit: 1646

Examiner: Nirmal Singh Basi

BRIEF ON APPEAL

MS Appeal Brief - Patents
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

A Notice of Appeal was filed in this case on 24 June 2005, thus setting a date for filing of the Brief of 24 August 2005. A petition for an extension of time of one (1) month until 24 September 2005 is enclosed along with the required fee. Claims 25-34, 37 and 40 are subject to this Appeal.

09/16/2005 NNGUYEN1 00000041 031952 09346794

01 FC:2402 250.00 DA

1. Real Party in Interest

The real party in interest is the assignee herein, NeuroMed Technologies Inc.

2. Related Appeals and Interferences

There are no related appeals or interferences known to appellant, the assignee or their representatives.

3. Status of Claims

During prosecution, there was some confusion concerning claim numbering in the course of various amendments and responses filed. Claims 1-24 were filed originally with this application. Claims 1-24 were canceled in an amendment filed 18 July 2001 and claims 25-33 were added. Claims 32 and 33 were canceled in an amendment filed 2 October 2002. This was forgotten, apparently, and new claims were filed numbered 32-40 in an amendment filed 14 October 2004. These claims should have been numbered 34-42. This has been done in the claims presented in section 8 of the Brief herein, and the numbering is adhered to in this status report.

Therefore, of the 42 claims pending at some point during the prosecution, claims 1-24, 32-33, 35-36, 38-39 and 41-42 have been canceled. The remaining claims, claims 25-34, 37 and 40, are rejected and are appealed.

4. Status of Amendments

Claims 25, 28 and 31 were amended to delete reference to non-elected inventions and claims 35-36, 38-39 and 41-42 were canceled for the same reasons in response to the final Office action. This amendment was entered.

5. Summary of Claimed Subject Matter

All claims are directed to screening methods to identify compounds that modulate T-type calcium channel activities. The compounds thus identified are candidate pharmaceuticals for

treating conditions that are affected by the activity of T-type calcium ion channels. These conditions include epilepsy, migraine, ataxia, schizophrenia, hypertension, arrhythmia, angina, depression, small lung carcinoma, Lambert-Eaton syndrome, and Parkinson's disease (page 9, lines 4-9).

T-type calcium channels include α_{1G} , α_{1H} , or α_{1I} subunits (see page 7, lines 5-13). These α_1 subunits can function alone or may be assembled with other proteins (page 7, lines 9-10, see also page 9, lines 1-3). It is known, in general, that α_1 subunits may be associated with any of four known β subunits which may modify the behavior of the α_1 subunit (page 5, lines 1-11).

The claims specifically employ the α_{1G} subunit derived from rat brain, the coding sequence for which is SEQ ID NO: 23, or a similarly functional α_{1G} subunit encoded by a sequence highly homologous to SEQ ID NO: 23. (Page 16, lines 1-3 and 10-12.) That is, the α_1 subunit functional as a T-type calcium ion channel required by the claims must be encoded by a nucleotide sequence that hybridizes to SEQ ID NO: 23 under conditions of stringency corresponding to washing at 62°C in 0.2 x SSPE/0.1% SDS. (Page 22, lines 18-19.) The DNA represented by SEQ ID NO: 23 was confirmed to function as a calcium ion channel α_1 subunit. Please see page 25, lines 18, *et seq.*, which provide experimental results demonstrating the behavior of the proteins encoded by SEQ ID NO: 23 to be the behavior of a calcium channel T-type subunit α_1 .

Cell lines transfected with an expression system for an α_{1G} subunit can be used to screen for compounds with pharmacological activity as described on page 17, lines 13-24. The analysis may be by simple binding (lines 11-14) or may be through electrophysiological effects (lines 14-17) or by a high-throughput assay involving fluorescent dye (lines 18-20). The compounds may be either agonists or antagonists (lines 21-24).

Claim 25 and its dependent claims 26-27 and 34 are specifically directed to a method to identify agonists; claims 28 and its dependent claims 29-30 and 37 are directed to identifying antagonists; and claim 31 and its dependent claim 40 is directed to prescreen for potential agonists or antagonists by simply measuring binding. Claims 25 and 28 measure calcium ion channel

activity which may be done by measuring the current (claims 26 and 29) or through a high-throughput assay (claims 27 and 30). Dependent claims 34, 37, and 40 are specific for SEQ ID NO: 23.

6. Grounds of Rejection to be Reviewed on Appeal

There is only one ground for rejection – all claims are rejected under 35 U.S.C. § 112, paragraph 1/§ 101 based on the assertion that any compounds identified by the method of the invention lack utility. There appears to be no assertion that the invention as claimed lacks written description or that the skilled artisan would not be able to perform the steps required by the claims in order to make a determination that a compound is or is not an agonist or antagonist of T-type calcium channel activity.

7. Argument

Introduction

The “lack of utility” argument applied to all appealed claims appears to rely on two sets of cited documents. In one set are papers by Sylvie (sic) Ertel, S, *et al.*, *TIPS* (1997) 18:37-42 and Williams, M.E., *et al.*, *Neuron* (1992) 8:71-84. These articles are adduced to support the proposition that, even after an agonist or antagonist is identified, it has no known utility. The second set of articles includes Bork, P., *et al.*, *Nature Genetics* (1998) 18:313-318; Bork, P., *et al.*, *Opinion in Structural Biology* (1998) 8:331-332; and Karp, P. D., *Bioinformatics* (1998) 14:753-754. These documents are cited to show that predicting functions from protein sequences is not a perfect science.

SEQ ID NO: 23 Has Been Demonstrated to Encode a Functional T-type α_1 Subunit

Appellants begin by addressing the second set of documents. In the context of the present claims, these documents, whatever their validity, appear irrelevant. The protein encoded by SEQ ID NO: 23 has been verified in the application itself by experimental data to encode an α_1 subunit of a T-type channel. Experiments establishing this are set forth in Example 5. So, clearly, it

is unnecessary to deduce the activity of the protein encoded by SEQ ID NO: 23 by analyzing the amino acid sequence it encodes. The manner of such proof is also set forth clearly in this Example and any polypeptide encoded by sequences that hybridize under the specified conditions to SEQ ID NO: 23 could readily be verified to encode a functional α_1 T-type subunit using the same disclosed method. There is no suggestion in the specification that the biological activity of the sequences required in the claims be deduced by analyzing the protein sequences. Therefore, these documents are irrelevant.

This having been said, appellants point out that the point of view set forth in these documents does not establish that establishing function on the basis of structure is useless. The article by Bork in *Nature Genetics*, for example, provides an entire page (314) of examples showing successful identification of function from structure, and the paper merely comments that the process can be improved. The authors comment on page 317, right-hand column, that “the incorporation of known functional information into databases at various levels is a pressing need...,” that “a comprehensive, precisely defined, and standardized classification of biological function is required for automation...,” and cite various other identified problems that are unrelated to directly testing whether a protein encoded by a similar nucleotide sequence has or does not have an α_1 T-type calcium ion channel function. Even the Bork editorial in *Current Opinion* states merely that structural similarity does not lead to “iron-clad” functional predictions; in the context of this article, this statement has little to do with the scope of the present claims. Similarly, the editorial in *Bioinformatics* relates simply to generic “*in silico*” determination of function, not the type of structural similarity and experimental confirmation described in the present application.

Thus, it appears that these articles are neither completely deprecating of structure / function analysis nor, more importantly, are they relevant to the present claims.

Neither Williams nor Ertel Show Lack of Utility

The other pair of articles appears equally irrelevant. Williams (1992) is cited as teaching that entry of calcium through voltage-dependent calcium channels in neurons controls diverse

functions such as neurotransmitter release, excitability, and differentiation. First, the article does not even pertain to the T-type calcium ion channels that are the subject of the present invention. Second, while these functions may be “diverse,” all of them relate to enhancing neural activity; thus, to the extent that neural activity should be depressed as, for example, in the case of epilepsy, modulation of these diverse functions would all be desirable in treatment.

Application of the Ertel (1997) article is clearly misplaced. The article by Ertel is a report of a meeting in which various scientific groups reported on their studies of low-voltage activated T-type calcium channels. A major problem noted repeatedly in Ertel is the absence of available T-type channel clones. Column 1 on page 37 states, “In addition, its molecular structure has never been defined, despite numerous attempts to sequence and clone it,” and in the summary, the authors point out that advances have been hampered by many factors, including “lack of a cloned channel.” Ertel concludes by saying that recent results suggest that any barriers to understanding the T-type channels might soon be abolished by, among other factors, the fact that “many groups claim to be close to cloning a T channel.”

Of course, the present specification overcomes this major barrier to understanding the mechanism of function of T-type calcium ion channels by providing a full-length clone, which is a feature of the claims.

In any event, Ertel never takes the view that T-type channel malfunction cannot be linked to specific diseases.

Quite the contrary, despite the lack of available clones, Ertel notes several instances where the role of T-type channels in diseases and undesired conditions is clear. Page 41, middle paragraph, notes:

Another system where a role for T channels is fairly clear is in the generation of rhythmic activity in some neuronal structures: indeed, anticonvulsants are probably the most prolific therapeutic field for T-channel blockers.

Pages 40-41, bridging paragraph, notes that

[T]hese channels would be very advantageous in hypertensive therapy because of the resulting reduction in circulating catecholamines.

Ertel also includes the report that mibefradil, which is a calcium ion channel, is specific for T channels. The clinical advantages of mibefradil are cited in the left hand column on page 38.

In sum, neither of the cited documents support the Examiner's view that compounds identified according to the methods of the invention lack utility.

The Specification Clearly Describes a Real World Utility

The specification itself identifies conditions for which compounds identified in the claimed method would be candidate therapeutics. These indications are listed on page 9 of the specification, second full paragraph, as including epilepsy, migraine, ataxia, schizophrenia, hypertension, arrhythmia, angina, depression, small cell lung carcinoma, Lambert-Eaton syndrome and Parkinson's disease. The adequacy of this disclosure is discussed in more detail below.

However, it is pointed out now that there is a great deal of documentary evidence already of record that T-type calcium ion channel modulators do have clinical function. This evidence was attached as exhibits to a Request for Continued Examination filed 26 March 2004. None of this evidence is even mentioned in the subsequent Office action. Exhibits A through G, included in this submission and attached in section 9 of this Brief concern clinical and animal model studies of mibefradil, which selectively blocks T-type calcium channels and apparently has some effect on L-type calcium channels as well. In Exhibit A, this compound is demonstrated to decrease heart rate and blood pressure in hypertensive patients; in Exhibit B, it is shown to be safe for patients with congestive heart failure; Exhibits D, E and F represent animal studies which show beneficial effects on the cardiovascular system. Exhibit G is a study in rats using this compound which posits a beneficial effect in NOD mice. Exhibit C is particularly important because it indicates that although the mibefradil compound is considered a selective T-type blocker, it also effects L-type calcium channels. Because of this lack of complete specificity, according to Exhibit C, there is concern that

the L-type blockade may depress myocardial performance. This indicates the importance of identifying additional compounds that are T-type channel selective.

Clearly this submitted evidence demonstrates that modulators of T-type activity can be considered for clinical development; the conditions mentioned are among those described in the specification, such as hypertension and arrhythmia.

No account has been taken of any of this evidence by the Examiner in the subsequent Office action.

Also submitted 26 March 2004 was the declaration of Dr. Terrance Snutch (Exhibit I).^{*}
Dr. Snutch states:

1. That abnormal T-type activity is associated with cardiac conditions, including pacemaker activity, cardiac hypertrophy, and hypertension;
2. That abnormal T-type function is associated with neurological diseases wherein neuronal bursts are abnormally fired, causing spastic convulsions and thus associated with epilepsy;
3. That abnormal function of the T-type ion channel is associated with impaired fertility because of its effect on hormone secretion.

Supporting documents for these statements were attached to the declaration.

Dr. Snutch also stated that, while there are several T-type calcium channels found in a single individual which vary slightly in structure and demonstrably in terms of their distribution

^{*} This declaration was actually first submitted very early in the prosecution on 18 July 2001 in response to a non-final Office action. In the Office action that followed, dated 10 October 2001, the declaration was acknowledged, but not substantively addressed. Indeed, its substance was entirely ignored. In a response filed by applicants on 10 April 2002, this was pointed out, but in the subsequent Office action mailed 2 July 2002, the declaration was ignored altogether. The failure of the Examiner to consider this declaration was again noted in a response filed 2 October 2002, but subsequent Office actions continued to ignore this declaration.

among tissues, this does not affect the usefulness of screening assays because the particular T-type calcium channel involved in a particular condition may depend on its tissue distribution and that all of the T-type channels have similar binding specificities. As noted by Dr. Snutch, “Any arbitrarily chosen T-type channel could be expressed in the cell line for use in screening assays to identify (compounds) ... useful in treating the conditions associated with any T-type channel.”

The Examiner states merely that this declaration has been considered, but that “it does not demonstrate that the claimed screening methods are useful for identifying molecules that treat specific T-type calcium channel related diseases.” (Page 19 of the final rejection.) No reason for this conclusion is ever provided.

Thus, the evidence submitted by appellants that compounds identified in the claimed assays would be useful as candidates for therapeutic drugs has either simply been ignored, or brushed off without explanation.

The Position of the Examiner Does Not Conform to PTO Guidelines or Federal Circuit Law

Respectfully, the criticisms repetitively leveled by the Examiner are characteristic of all screening assays for all candidate drugs. It is always the case that just because a compound passes a screen does not mean that it is likely to treat a disease. It is always true that interfering with a metabolic activity may be detrimental to a cell. It is always true that compounds identified in screening assays must be subjected to further tests and development before they are considered for clinical assessment. It is always true that few, if any, of compounds that are identified in a screen go on successfully actually to treat a condition or disease. Despite these limitations, screening assays are widely used by the pharmaceutical industry at the expense of millions of dollars. If these are so useless, then why are so many pharmaceutical company resources expended on them, and so many resources expended on developing them?

And it is not as if no specific diseases are mentioned as those for which the identified drugs are candidates. The Examiner himself lists them on page 7 of the final rejection. The statement that, “The specific dysfunction associated T-type ion channel of SEQ ID NO: 23 is not

known or disclosed in the *prior art*” is clearly not relevant, since the specification itself describes these diseases. The Examiner goes on to state that “not a single compound has been isolated by the claimed method that treats a specific disease.” Another irrelevant statement especially in view of the fact that evidence of record shows that the T-type channel inhibitor mibefradil is actually in clinical trials for treatment of hypertension.

The standard that appears to be evinced by the outstanding rejection is not that sanctioned by the Office. As pointed out in the Response to Final Rejection, the Guidelines on Utility themselves state:

Courts have found repeatedly that the mere identification of a pharmacological activity of a compound that is relevant to an asserted pharmacological use provides an “immediate benefit to the public” and thus satisfies the utility requirement. As the CCPA held in Nelson v. Bowler:

Knowledge of the pharmacological activity of any compound is obviously beneficial to the public. It is inherently faster and easier to combat illnesses and alleviate symptoms when the medical profession is armed with an arsenal of chemicals having known pharmacological activities. Since it is crucial to provide researchers with an incentive to disclose pharmacological activities in as many compounds as possible, we conclude that adequate proof of any such activity constitutes a showing of practical utility.

Similarly, courts have found utility for therapeutic inventions despite the fact that an applicant is at a very early stage in the development of a pharmaceutical product or therapeutic regimen based on a claimed pharmacological or bioactive compound or composition. Accordingly, Office personnel should not construe § 101, under the logic of “practical” utility or otherwise, to require that an applicant demonstrate that a therapeutic agent based on a claimed invention is a safe or fully effective drug for humans.

The most recent case of which appellants are aware in which the Federal Circuit considered the question of utility as a basis for rejection is *Rasmusson, et al., v. SmithKline Beecham*, 413 F3d 1318, 75 USPQ 2d 1297 (Fed. Cir. 2005). In this case, the Court considered

claims in competing applications directed to a method to treat a type of prostate cancer by administering finasteride, which is a selective inhibitor of 5- α -reductase. The applications filed by Rasmusson, apparently, did not contain any data demonstrating the effectiveness of finasteride in treating this condition and the claims were rejected for lack of utility. Rasmusson filed a series of continuations over the years, and the Court found the claims to meet the utility requirement only when the art had progressed to the point where the utility would be considered acceptable in the eyes of the skilled practitioner. The Court did appear to cite conflicting articulations of this standard, citing *In re Brana* that

A specification disclosure which contains a teaching of the manner and process of making and using the invention...must be taken as in compliance with the enabling requirement of the first paragraph of § 112 unless there is reason to doubt the objective truth of the statements contained therein which must be relied on for enabling support.

(*In re Brana*, 51 F3d 1650, 34 USPQ2d 1436 (Fed. Cir. 1995), quoting *In re Marzocchi*, 439 F2d 220, 223, 169 USPQ 367 (CCPA 1971) and a number of cases making similar statements. Alternatively, the Court quotes *In re Novak*, 306 F2d 924 (CCPA 1962) for the proposition that “where there is no indication that one skilled in the art would accept without question statements [as to the effects of the claimed drug products] and no evidence has been presented to demonstrate that the claimed products do have these effects” the applicant has failed to demonstrate sufficient utility.

It does not appear that these standards are entirely consistent; however, in the present case both are met. Attached to the response filed 26 March 2004, as Exhibits L and M, are two granted U.S. patents: U.S. 6,358,706; and U.S. 6,309,858. The claims in the ‘706 patent are directed to isolated and purified DNA that encodes an α_{1G} channel protein, an expression vector for this protein and recombinant cells that produce it. According to the summary of the invention,

The recombinant protein is useful to identify modulators of the α_{1G-C} calcium channel. Modulators identified in the assay disclosed herein are useful as therapeutic agents and are candidates for treatment of disorders that are mediated by human α_{1G-C} activity.

These activities are listed as including “epilepsy, schizophrenia, depression, sleep disorders, stress, endocrine disorders, respiratory disorders, peripheral muscle disorders,” and a retinue of others including hypertension and cardiac arrhythmia. This patent has a filing date of 26 October 1999, which is roughly contemporaneous with the filing date herein.

The ‘858 patent similarly has claims directed to DNA sequences encoding a T-type α_1 subunit where, again, the utility of the encoding sequence is said to reside in its use in diagnosing diseases that are associated with expression of T-type activity (including pain, peripheral pain, cancer pain and the like (column 21, lines 51-56)) and especially to assays for identifying compounds that modulate ion channel activity, which generate candidate compounds useful for the treatment or prophylaxis of pain (column 19, lines 16-26 and lines 63-67). (Pain is among the indications noted in the present application, as migraine is listed as an indication.) The ‘858 patent issued on an application filed 23 September 1999, again roughly contemporaneous with the present application and is based on a provisional application filed 29 September 1998, well before the present application date.

Granted U.S. patents have a presumption of validity; if the ‘706 and ‘858 patents are valid, their disclosures must be sufficient to support the utility of the claimed DNA. *Thus, the existence of these issued claims is clearly evidence that the utility of providing a screen for modulators of T-type channel activity is sufficient to support patentability of materials useful in such screens, and therefore sufficient to support utility of the screens itself.*

It will be noted that appellants are not claiming that the issuance of these patents is binding precedent for the issuance of the present claims; they are cited as probative of the recognition by the art of utility for screening assays such as those claimed.

In addition, publications available in the art as of the application date 2 July 1999 clearly show acceptance that modulators of T-type calcium channel activity would be useful in specific disease conditions named in the specification. These documents are cited in Dr. Snutch’s declaration described above.

Thus, it is clear that even the perhaps surprisingly strict standard elucidated in *Rasmusson* is met in the present instance.

Summary

In summary, the Examiner has not made out a *prima facie* case of lack of utility. The documents cited by the Examiner in support of his position are either irrelevant (in the case of documents cited to show that structure/function correlations are not perfect, because such correlations are not relied upon in the present case) or are not probative (in the case of the two documents which purport to show lack of nexus between T-type calcium channel modulation and specific disease conditions, as one publication relates to other types of calcium channels and precedes the application date by seven years, and the other is based on the lack of availability of cloned T-type channels, a problem remedied by the present invention). In addition, the latter set of documents actually supports appellants' contention that such a nexus exists.

Even if the Examiner were justified in requesting evidence, such a request has been met. This evidence has been either ignored by the Examiner (in the case of documents showing that selective T-type channel inhibitors are in fact in the clinic for conditions noted in the specification) or brushed off without sufficient rationale (as in the case of the Declaration of Dr. Snutch). In addition, the position taken by the Examiner is contrary to that set forth in the Guidelines and appellants have demonstrated that the utility standard set by the Federal Circuit in its most recent decision has, in fact, been met. Appellants therefore request that the rejection be withdrawn and that claims 25-34, 37 and 40 be passed to issue.

8. Claims Appendix

An Appendix containing a copy of the claims as currently pending is attached.

As noted above, the error in claim numbering that occurred during prosecution has been corrected in this Appendix. Claims 32-40 referred to in the cover page of the Office action dated 25 January 2005 have been renumbered claims 34-42.

9. Evidence Appendix

Enclosed for the convenience of the Office are Exhibits A through M referred to in the argument section of the Brief which were submitted in response to a non-final Office action on 26 March 2004. Exhibit I in this set is the Declaration of Dr. Terrance Snutch; the remaining documents are publications or patents.

10. Related Proceedings Appendix


No related proceedings are referenced in 2. above, therefore no Appendix is included.

The Assistant Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. § 1.17 that may be required by this Brief, or to credit any overpayment, to **Deposit Account No. 03-1952.**

Respectfully submitted,

Dated: September 13, 2005

By:


Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125



CLAIMS APPENDIX

-24. (canceled)

25. (previously presented): A method to identify a compound which behaves as an agonist for a T-type calcium channel which method comprises:

a) contacting a recombinant cell which expresses the α_1 subunit of a heterologous T-type calcium channel with a compound to be tested; and

b) determining the ability of said compound to activate said α_1 subunit; wherein said α_1 subunit is functional as a T-type calcium ion channel and is encoded by a nucleotide sequence which hybridizes under conditions of stringency corresponding to washing at 62° C in 0.2 x SSPE/0.1% SDS to a nucleic acid comprising SEQ ID NO: 23 and

wherein said activating comprises enhancing the flow of calcium ions into said cell in the presence as compared to the absence of said compound;

whereby a compound which activates said α_1 subunit is identified as an agonist of said T-type calcium channel.

26. (previously presented): The method of claim 25 wherein said activation is measured by measuring the current through the calcium channel before and after said contacting of said cell with said compound.

27. (previously presented): The method of claim 25, wherein said cells contain a fluorescent dye sensitive to intracellular calcium concentration and said activation is determined by observing a change in the fluorescence of said dye when said contacting is performed.

28. (previously presented): A method to identify an antagonist of a T-type calcium channel which method comprises:

a) contacting a recombinant cell expressing the α_1 subunit of a heterologous T-type calcium channel with a known agonist of said T-type calcium channel;

b) contacting said cell with a compound to be tested; and

c) determining the ability of said compound to diminish the activation of said α_1 subunit by said agonist;

wherein said α_1 subunit is functional as a T-type calcium ion channel and is encoded by a nucleotide sequence which hybridizes under conditions of stringency corresponding to washing at 62° C in 0.2 x SSPE/0.1% SDS to a nucleic acid comprising SEQ ID NO: 23 and

wherein said activating comprises enhancing the flow of calcium ions into said cell in the presence as compared to the absence of said agonist;

whereby a compound which diminishes the activation of said α_1 subunit by said agonist is identified as an antagonist.

29. (previously presented): The method of claim 28 wherein said activation is measured by measuring the current through the calcium channel before and after said contacting of said cell with said compound.

30. (previously presented): The method of claim 28, wherein said cells contain a fluorescent dye sensitive to intracellular calcium concentration and said activation is determined by observing a change in the fluorescence of said dye when said contacting is performed.

31. (previously presented): A method to prescreen compounds as agonists or antagonists of T-type calcium ion channels by virtue of their ability to bind said T-type channels which method comprises:

a) contacting a recombinant cell expressing the α_1 subunit of a heterologous T-type calcium channel with a compound to be tested; and

b) determining the ability of said compound to bind to said cell expressing said α_1 subunit;

wherein said binding is determined by observing competitive binding with a known agonist or antagonist of said channel;

wherein said α_1 subunit is functional as a T-type calcium ion channel and is encoded by a nucleotide sequence which hybridizes under conditions of stringency corresponding to washing at 62°C in 0.2 x SSPE/0.1% SDS to a nucleic acid comprising SEQ ID NO: 23,

whereby a compound which is determined to bind said cell is identified as a compound which will behave as either an agonist or antagonist of a T-type calcium channel.

32-33. (canceled)

~~[[32]]~~ 34. (previously presented): The method defined in claim 25 wherein the nucleic acid comprises SEQ ID NO: 23.

~~[[33]]~~ 35. (canceled)

~~[[34]]~~ 36. (canceled)

~~[[35]]~~ 37. (previously presented): The method defined in claim 28 wherein the nucleic acid comprises SEQ ID NO: 23.

~~[[36]]~~ 38. (canceled)

~~[[37]]~~ 39. (canceled)

~~[[38]]~~ 40. (previously presented): The method defined in claim 31 wherein the nucleic acid comprises SEQ ID NO: 23.

~~[[39]]~~ 41. (canceled)

~~[[40]]~~ 42. (canceled)



EVIDENCE APPENDIX

This appendix contains, for the convenience of the Office, the following evidentiary material already of record:

- Exhibit A: Lacourciere, Y., *et al.*, *Am J Hypertens.* (1997) 10:189-196
- Exhibit B: van der Vring, J. A., *et al.*, *Clin Ther.* (1996) 18:1191-1206
- Exhibit C: Rousseau, M. F., *et al.*, *J Am Coll Cardiol.* (1996) 28:972-979
- Exhibit D: Karila-Cohen, D., *et al.*, *J Cardiovasc Pharmacol.* (1996) 28:271-277
- Exhibit E: Vacher, E., *et al.*, *J Cardiovasc Pharmacol.* (1996) 27:686-694
- Exhibit F: Schmitt, R., *et al.*, *Cardiovasc Drugs Ther.* (1996) 10:101-105
- Exhibit G: Wang, L., *et al.*, *Diabetes* (1996) 45:1678-1683
- Exhibit H: Kito, M., *et al.*, *Seizure* (1996) 5:115-119
- Exhibit I: Declaration of Dr. Terrance Snutch
- Exhibit J: Williams, M. E., *et al.*, *Science* (1992) 257:389-395
- Exhibit K: Williams, M. E., *et al.*, *Neuron* (1992) 8:71-84
- Exhibit L: U.S. patent 6,358,706
- Exhibit M: U.S. patent 6,309,858

□ Am J Hypertens. 1997 Feb;10(2):189-96.

The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.

Lacourciere Y, Poirier L, Lefebvre J, Archambault F, Dalle Ave S, Ward C, Lindberg E.

Hypertension Unit, le Centre Hospitalier de l'Universite Laval, Saint-Foy, Quebec, Canada.

Mibefradil is a novel calcium antagonist that blocks selectively the T-type calcium channels. In this double-blind forced titration study design we compared the effects of mibefradil 50, 100, and 150 mg and nifedipine GITS 30, 60, and 90 mg monotherapies or combined with lisinopril 20 mg in 71 moderate to severe hypertensives (59 men and 12 women) with confirmed ambulatory hypertension. An incremental dose-response effect was observed both in clinic and ambulatory blood pressure parameters during treatment with mibefradil and nifedipine GITS alone and combined with lisinopril. At maximal dosage, patients treated with mibefradil experienced a greater ($P < .05$) reduction in clinic and ambulatory diastolic blood pressures as well as a greater response rate (86% v 69%). Trough:peak ratios for systolic and diastolic blood pressures were $> 90\%$ at each dose level. Significant decrease in baseline heart rate was observed with mibefradil 150 mg alone or combined with lisinopril, but no patients experienced clinically significant atrioventricular conduction abnormalities. Adverse events related to vasodilation were more prevalent in the nifedipine GITS group. Consequently, the results of the present study demonstrate that the novel calcium channel blocker mibefradil, either alone or in combination with lisinopril, is effective in reducing clinic and 24-h blood pressures while decreasing heart rate and is well tolerated in patients with moderate to severe hypertension.

Publication Types:

- Clinical Trial
- Randomized Controlled Trial

PMID: 9037327 [PubMed - indexed for MEDLINE]

□ Clin Ther. 1996 Nov-Dec;18(6):1191-206.

Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.

van der Vring JA, Bernink PJ, van der Wall EE, van Velhuisen DJ, Braun S, Kobrin I.

Martini Ziekenhuis, Groningen, The Netherlands.

Mibefradil is a novel calcium antagonist belonging to a new chemical class of benzimidazolyl-substituted tetraline derivatives. The safety of mibefradil in patients with mild-to-moderate chronic congestive heart failure (CHF) due to coronary heart disease was assessed in a randomized, double-masked, placebo-controlled, multiple-ascending-dose trial in 45 patients. Patients were assigned to receive one of five dose levels (6.25, 12.5, 25, 50, or 100 mg/d) of mibefradil or placebo according to a randomization list. If safety variables remained stable, the subsequent group of patients was randomized to the next higher dose. The safety variables assessed included New York Heart Association class, vital signs, and ejection fraction. Patients were evaluated at baseline and day 8 of the dosing period. Mibefradil did not worsen clinical or cardiac variables. Approximately 23.3% (7 of 30) of the mibefradil-treated patients reported one or more adverse events compared with 13.3% (2 of 15) of the placebo group. The incidence of adverse events was not dose dependent. In summary, short-term oral dosing of mibefradil did not worsen measures of cardiac function in 30 patients with mild-to-moderate CHF.

Publication Types:

- Clinical Trial
- Multicenter Study
- Randomized Controlled Trial

PMID: 9001836 [PubMed - indexed for MEDLINE]

□ J Am Coll Cardiol. 1996 Oct;28(4):972-9.

Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction.

Rousseau MF, Hayashida W, van Eyll C, Hess OM, Benedict CR, Ahn S, Chapelle F, Kobrin I, Pouleur H.

Division of Cardiology, University of Louvain, Brussels, Belgium.

OBJECTIVES: This study sought to assess the hemodynamic and cardiac effects of two dose levels of mibefradil in patients with varying degrees of ischemic left ventricular dysfunction. **BACKGROUND:** Mibefradil is a new, selective T-type and L-type calcium channel blocking agent. Because L-type channel blockade may depress myocardial performance, an invasive hemodynamic study was performed to assess the safety of this agent. **METHODS:** We performed an open label study, examining the effects of two intravenous doses of mibefradil, selected to produce plasma levels comparable to those measured after oral administration of 50 mg (dose 1: 400 ng/ml) or 100 mg (dose 2: 800 ng/ml) of the drug. Variables studied included the indexes of left ventricular function and neurohormone levels. Patients were stratified according to ejection fraction (EF) ($>$ or $=$ 40%, $n = 26$; $<$ 40%, $n = 24$) and the presence ($n = 15$) or absence ($n = 35$) of heart failure. **RESULTS:** In patients with preserved systolic function, dose 1 had no clinically significant hemodynamic effects, but dose 2 decreased mean aortic pressure and systemic vascular resistance (-8.5 mm Hg, -12% , both $p < 0.01$) and also reduced end-systolic stress and volume, thus improving EF (52% to 58%, $p < 0.01$). Heart rate tended to decrease. In patients with depressed EF, heart rate decreased significantly with both doses. The effects of dose 1 mimicked those observed after dose 2 in patients with preserved EF. Dose 2 (plasma levels $1,052 \pm 284$ ng/ml) still decreased left ventricular systolic wall stress and improved EF (24.0% to 28.5%, $p < 0.05$) but also significantly depressed the maximal first derivative of left ventricular pressure. Examination of individual pressure-volume loops in two patients with heart failure showed a clear rightward shift of the loop despite a decrease in systolic pressure, suggesting negative inotropy. Neurohormone levels were unchanged at both dose levels and in all subgroups. **CONCLUSIONS:** Intravenous mibefradil was well tolerated and produced an overall favorable cardiovascular response. However, high plasma concentrations might produce myocardial depression in patients with heart failure, and caution should be exerted in this setting.

Publication Types:

- Clinical Trial
- Multicenter Study

PMID: 8837576 [PubMed - indexed for MEDLINE]

□ J Cardiovasc Pharmacol. 1996 Aug;28(2):271-7.

Effects of mibefradil on large and small coronary arteries in conscious dogs: role of vascular endothelium.

Karila-Cohen D, Dubois-Rande JL, Giudicelli JF, Berdeaux A.

Department de Pharmacologie, Faculte de Medecine Paris-Sud, France.

The systemic and coronary hemodynamic effects of mibefradil, a "nondihydropyridine" calcium antagonist acting on both L- and T-type calcium channels, were investigated in chronically instrumented conscious dogs before and after local endothelium removal of the circumflex coronary artery by angioplasty. After intravenous infusion, mibefradil (0.2 mg kg⁻¹ min⁻¹) decreased mean arterial blood pressure (MAP; -15 +/- 1%), increased heart rate (HR; 58 +/- 9%), and coronary blood flow (CBF; 103 +/- 14%) (all p < 0.05). Before endothelium removal, mibefradil increased the diameter of the left circumflex epicardial coronary artery (LCX) by 7.8 +/- 1.2% from 3,006 +/- 219 microns, but this dilatory effect was significantly reduced by 69% (p < 0.001) and 45% (p < 0.01), 3 and 21 days after endothelium removal, respectively. Mibefradil also reduced by 46% (p < 0.01) the potent coronary constrictor effect of ergonovine (300 micrograms intravenous bolus). These results demonstrate that mibefradil is a potent dilator of large and small coronary arteries in conscious dogs and that approximately 30% of its dilatory effect on large coronary artery is endothelium-independent. In addition, mibefradil prevents ergonovine-induced epicardial coronary constriction.

PMID: 8856484 [PubMed - indexed for MEDLINE]

□ J Cardiovasc Pharmacol. 1996 May;27(5):686-94.

Mibefradil, a selective calcium T-channel blocker, in stroke-prone spontaneously hypertensive rats.

Vacher E, Richer C, Fornes P, Clozel JP, Giudicelli.

Departement de Pharmacologie, Faculte de Medecine Paris-Sud, Le Kremlin-Bicetre, France.

Several types of antihypertensive agents, including calcium antagonists, have been reported to prevent stroke and prolong survival in stroke-prone spontaneously hypertensive rats (SHR-SP). We investigated whether mibefradil, a new calcium antagonist acting selectively at the level of T-type calcium channels, would be able to (a) limit or prevent the structural and functional alterations that develop in the cerebral arteries of SHR-SP before stroke and (b) suppress stroke and prolong survival. Mibefradil (30 mg/kg/day) was given orally to young salt-loaded SHR-SP from age 5 weeks to age 20 weeks. Blood pressure (BP) (in conscious animals), diuresis, and proteinuria were determined weekly. After 1012 weeks of treatment, middle cerebral arteries and aortas were removed from randomly selected control and treated SHR-SP. Aortic media thickness and collagen density were evaluated by histomorphometry. Middle cerebral arteries were mounted in a myograph for wall thickness determination and isometric tension recordings. Mibefradil completely prevented stroke and mortality, significantly limited the increase in BP, and opposed the increases in diuresis and proteinuria observed in controls. Simultaneously, mibefradil abolished vascular fibrinoid necrosis formation in the brain and reduced arterial thickening in the cerebral artery as well as in the aorta. The maximal contractile responses of the cerebral arteries to potassium chloride and serotonin were greater in mibefradil-treated animals than in controls, as were the endothelium-dependent relaxant responses. Mibefradil, chronically administered to young SHRSP in a dose that limits the development of hypertension not only prevents stroke and mortality but also affords protection against the vascular structural alterations which develop with age in these animals and preserves or improves the cerebral artery's smooth muscle and endothelial cell functions.

PMID: 8859939 [PubMed - indexed for MEDLINE]

- Cardiovasc Drugs Ther. 1996 May;10(2):101-5.

Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition.

Schmitt R, Clozel JP, Iberg N, Buhler FR.

Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Cilazapril, an angiotensin-converting enzyme inhibitor, and mibefradil, a selective T-type voltage-operated calcium channel blocker, have been shown to prevent neointima formation after vascular injury. The goal of the present study was to evaluate the mechanism of action of both drugs. For this purpose, the influence of the renin angiotensin system on the effects of mibefradil (30 mg/kg po) and cilazapril (10 mg/kg po) on neointima formation after carotid injury were evaluated in normotensive rats (normal renin angiotensin system) and DOCA hypertensive rats (suppressed renin angiotensin system). In addition, in order to differentiate an effect on cell migration or cell proliferation, both drugs were given either before or after the smooth muscle migration phase. Finally, cilazapril and mibefradil were given in combination. In normotensive rats, mibefradil and cilazapril decreased neointima formation, resulting in neointima/media ratios of 38% ($p < 0.05$) and 53% ($p < 0.01$), respectively. However, in DOCA hypertensive rats, mibefradil was active, with a reduction of the neointima/media ratio by 63% ($p < 0.001$), whereas cilazapril reduced it only slightly (19%) and not significantly. In addition, cilazapril was active only when treatment started before the migration phase (63%, reduction in neointima/media ratio, $p < 0.001$) but not when started thereafter (13% reduction in neointima/media ratio, n.s.). In contrast, treatment with mibefradil was also active when started after the migration phase (51% reduction in neointima/media ratio, $p < 0.001$ when treatment started 1 day before balloon injury and 41%, $p < 0.01$ when treatment started 5 days after balloon injury). The combination of both drugs was additive (67% reduction in neointima/media ratio, $p < 0.001$ vs. control). These experiments clearly show that mibefradil and cilazapril have a different mechanism of action after vascular injury. Mibefradil most likely prevents the proliferation of smooth muscle cells. In contrast, cilazapril most likely inhibits the migration of smooth muscle cells. These two different mechanisms of action explain why the effects of both drugs are additive.

PMID: 8842500 [PubMed - indexed for MEDLINE]

□ Seizure. 1996 Jun;5(2):115-9.

Mechanisms of T-type calcium channel blockade by zonisamide.

Kito M, Maehara M, Watanabe K.

Department of Pediatrics, Minami Seikyo Hospital, Nagoya, Japan.

We investigated the effects of zonisamide, a new antiepileptic drug, on voltage-dependent T-type calcium current (ICa) in cultured neuroblastoma cells of human origin (NB-I). Zonisamide reduced T-type ICa in a concentration-dependent manner without evoking any change in its inactivation kinetics or voltage dependence of action. The mean percent reduction was 38.3 +/- 5.8% at 50 microM. Further, zonisamide shifted the inactivation curve approximately 20 mV negative compared to the control. These resting blocking actions suggest that zonisamide shifts the channel population toward the inactivation state, allowing fewer channels to open during membrane depolarization. The blockade of T-type calcium channels by zonisamide could suppress an important component of inward current that underlies epileptiform cellular bursting, thereby inhibiting the spread of seizure activity.

PMID: 8795126 [PubMed - indexed for MEDLINE]

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on July 18, 2001.

Tami M. Procopio
Tami M. Procopio

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Terrance P. SNUTCH, *et al.*

Serial No.: 09/346,794

Filing Date: 02 July 1999

For: NOVEL HUMAN CALCIUM
CHANNELS AND RELATED PROBES,
CELL LINES AND METHODS

Examiner: Nirmal S. Basi

Group Art Unit: 1646

DECLARATION OF DR. TERRANCE SNUTCH

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

I, Terrance Snutch, declare as follows:

1. I am a co-inventor of the subject matter claimed in the above-referenced application and have been practicing in the field of molecular biology, and specifically in the field of ion channels, for over 15 years. A copy of my *curriculum vitae* is attached hereto as Exhibit A. I have published many papers on the structure and function of calcium channels and am considered one of the leading researchers in this field.

2. The association of abnormal T-type calcium channel activity with specific conditions is well known in the art. Enclosed herewith are a number of documents which verify this. Abnormal T-type activity is associated with a number of cardiac conditions including

pacemaker activity (Hajiwara, *et al.*, *J. Physiol.* (1988) 395:233-253; cardiac hypertrophy (Nuss, *et al.*, *Circ. Res.* (1995) 73:777-782); and hypertension (Self, *et al.*, *J. Vasc. Res.* (1994) 31:359-366). Abnormal T-type calcium function is also associated with neurological diseases wherein neuronal bursts are abnormally fired causing spastic convulsions (Huguenard, *Ann. Rev. Physiol.* (1996) 58:329-348) and thus associated with epilepsy (Tsakiridou, *et al.*, *J. Neuro. Sci.* (1995) 15:3110-3117; Coulter, *et al.*, *Brit. J. Pharmacol.* (1990) 100:800-806). Abnormal function of the T-type calcium ion channel is also associated with impaired fertility because of its effect on hormone secretion (Rossier, *et al.*, *Endocrinology* (1966) 137:4817-4826; Arnoult, *et al.*, *Proc. Natl. Acad. Sci. USA* (1996) 93:13004-13009). Copies of these documents are attached hereto. Thus the conditions associated with abnormal T-calcium channel function are well established and agonists and antagonists of T-type calcium channels are useful in treating these conditions.

3. There are several T-type calcium channels found in a single individual which vary slightly in structure and demonstrably in terms of their distribution among various tissues. This, however, does not affect the usefulness of screening assays for agonists and antagonists. The particular T-type calcium channel involved in a particular condition may depend on its tissue distribution; for instance, T-type channels found in the nervous system are associated with epilepsy and neurological diseases in general where spastic convulsions are involved. However, it is not necessary to understand which particular T-type calcium channel is being used in a screen for compounds that would be useful in treating, for example, these convulsive conditions because of the similarity in the binding specificity of all T-type channels. In very simple terms, compounds which are found to inhibit or stimulate the activity of nervous T-type channels will also inhibit or stimulate the activity of T-type channels found in other tissues. Thus, any arbitrarily chosen T-type channel could be expressed in a cell line for use in screening assays to identify agonists or antagonists and the agonists or antagonists would be useful in treating the conditions associated with any T-type channel. As noted above, abnormal T-type activity is associated with a number of cardiac conditions, with hypertension, with neurological diseases involving spastic convulsions, and with impaired fertility. An agonist or antagonist identified with regard to any T-type channel would be useful in any and all of these conditions.

4. This pattern of similar binding activity among all T-type channels can be analogized to such a pattern among L-type channels. All of the T-type channels have similar

behaviors in that they activate at low membrane potential, have small single channel conductance, have negative steady state inactivation properties, and contribute to spike firing patterns and rhythmic bursting processes. Analogous to the T-type channel another type of channel linked by similar behaviors is the L-type. There are several α_1 subunits associated with various L-type channels - i.e., α_{1S} , α_{1C} , and α_{1D} and each is encoded by a distinct gene and exhibits a distinct distribution pattern. For example, α_{1S} is in skeletal muscle; α_{1C} is in neurons and cardiac and smooth muscle; and α_{1D} is found in neurons and endocrine cells. They can be discriminated from all other types of calcium channels by their common sensitivity to 1,4-dihydropyridines. Thus, any one of these genes could be used to generate an L-type calcium channel for use in a cell-based assay to identify interacting compounds. These interacting compounds bind to all L-type channels and thus are useful in treating conditions related to any one of them.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Executed at VANCOUVER, B.C. on 10 July 2001.


Terrance Snutch

concentrations of L-Arg (5 to 100 mM) to muscles treated with L-NMMA and TNF- α resulted in a more pronounced negative inotropic effect than that seen with TNF- α alone [$19 \pm 4\%$ of baseline tension with TNF- α and L-Arg as compared to $59 \pm 7\%$ of baseline tension with TNF- α alone ($P < 0.01$, $n = 6$; Student's two-tailed t test)] (Fig. 4A). This suggests that L-Arg enhanced the negative inotropic effect of TNF- α by providing additional substrate for NO production. This effect was also greater than that seen with L-Arg (100 mM) alone ($31 \pm 6\%$ of baseline tension; $P < 0.01$, $n = 6$; Student's two-tailed t test). The addition of L-Arg (100 mM) to muscles treated with L-NMMA and IL-6 reduced tension to $35 \pm 3\%$ (Fig. 4B). The addition of L-Arg (100 mM) to muscles treated with L-NMMA and IL-2 reduced tension to $11 \pm 10\%$ of baseline (Fig. 4C). All of these inotropic effects were completely reversed within 30 min after the cytokines or other agents were washed away (Fig. 4, A through C). Removal of the endothelium did not alter the negative inotropic responses of the papillary muscles to cytokines (Fig. 4, A through C).

Cytokines increase the amount of NO in noncardiac tissues by inducing the transcription of an inducible NO synthase (13-16). The rapid onset and reversibility of the effects seen in this report argue against an effect requiring gene transcription. The negative inotropic effects of these cytokines in the papillary muscle preparation appear to result from enhanced activity of a constitutive NO synthase enzyme in the myocardium.

The observed inotropic effects of pro-inflammatory cytokines raise the possibility that they participate in reversible, postischemic myocardial depression ("stunning"). Myocardial stunning frequently occurs after cardiopulmonary bypass and may complicate successful recovery from cardiac surgery (5-9). We found elevated concentrations of IL-6 (1800 to 4000 U/ml) in bronchoalveolar fluid from patients after cardiopulmonary bypass (18). IL-6 also reversibly decreased tension generated by pectinate muscles removed from patients at the time of surgery (18). These preliminary observations in patients support the clinical relevance of our findings with the Syrian hamster papillary muscle preparation. Thus, the regulation of pro-inflammatory cytokines and myocardial NO synthase may provide new therapeutic strategies for the management of cardiac patients.

REFERENCES AND NOTES

1. J. Van Damme et al., *J. Exp. Med.* 165, 914 (1987).
2. R. D. Garman, K. A. Jacobs, S. C. Clark, D. H. Raulet, *Proc. Natl. Acad. Sci. U.S.A.* 84, 7629 (1987).

3. A. Naldini, W. R. Fleischmann, Z. K. Ballas, K. D. Klimpel, G. R. Klimpel, *J. Immunol.* 139, 1880 (1987).
4. B. Beutler and A. Cerami, *Annu. Rev. Immunol.* 7, 625 (1989).
5. R. Engler and J. W. Covell, *Circ. Res.* 61, 20 (1987).
6. B. R. Lucchesi, S. W. Werns, J. C. Fantone, *J. Mol. Cell. Cardiol.* 21, 1241 (1989).
7. L. O. Go et al., *Am. J. Physiol.* 255, H1188 (1988).
8. W. Westlin and K. M. Mullane, *Circulation* 80, 1828 (1989).
9. K. M. Mullane, W. Westlin, R. Kraemer, *Ann. N.Y. Acad. Sci.* 524, 103 (1988).
10. R. M. J. Palmer, D. S. Ashton, S. Moncada, *Nature* 333, 664 (1988).
11. L. J. Ignarro, G. M. Buga, K. S. Wood, R. E. Byrns, G. Chaudhuri, *Proc. Natl. Acad. Sci. U.S.A.* 84, 9265 (1987).
12. S. Moncada et al., *J. Cardiovasc. Pharmacol.* 17 (suppl. 3), S1 (1991).
13. S. J. Green, C. A. Nacy, M. S. Meltzer, *J. Leukocyte Biol.* 50, 93 (1991).
14. D. J. Stuehr, H. J. Cho, N. S. Kwon, M. F. Weise, C. F. Nathan, *Proc. Natl. Acad. Sci. U.S.A.* 88, 7773 (1991).
15. L. Li, R. G. Kilbourn, J. Adams, I. J. Fidler, *Cancer Res.* 51, 2531 (1991).
16. S. S. Gross, E. A. Jaffe, R. Levi, R. G. Kilbourn, *Biochem. Biophys. Res. Commun.* 178 (no. 3), 823 (1991).
17. A. M. Shah, J. A. Smith, M. J. Lewis, *J. Cardiovasc. Pharmacol.* 17 (suppl. 3), S251 (1991).
18. B. G. Hattler and M. S. Finkel, paper presented at the 20th Annual Meeting of the Keystone Symposium on Molecular and Cellular Biology, Steamboat Springs, CO, 1 April 1991.
19. M. S. Finkel, L. Shen, R. C. Romeo, C. V. Oddis, G. Salama, *J. Cardiovasc. Pharmacol.* 19, 610 (1992).
20. A. I. DeAgostini, S. C. Watkins, H. S. Slayter, H. Youssoufian, R. D. Rosenberg, *J. Cell Biol.* 111, 1293 (1991).
21. Supported by awards from the American Heart Association, (Western) Pennsylvania Affiliate, the Sarah and David Weis Cardiovascular Research Fellowship, and NIH grant No. GM-37753. We thank B. A. Busch for assistance in the preparation of this manuscript.

16 March 1992; accepted 21 May 1992

Structure and Functional Expression of an ω -Conotoxin-Sensitive Human N-Type Calcium Channel

Mark E. Williams, Paul F. Brust, Daniel H. Feldman, Saraswathi Patthi, Susan Simerson, Azarnoush Maroufi, Ann F. McCue, Gönül Veliçelebi, Steven B. Ellis, Michael M. Harpold*

N-type calcium channels are ω -conotoxin (ω -CgTx)-sensitive, voltage-dependent ion channels involved in the control of neurotransmitter release from neurons. Multiple subtypes of voltage-dependent calcium channel complexes exist, and it is the α_1 subunit of the complex that forms the pore through which calcium enters the cell. The primary structures of human neuronal calcium channel α_{1B} subunits were deduced by the characterization of overlapping complementary DNAs. Two forms (α_{1B-1} and α_{1B-2}) were identified in human neuroblastoma (IMR32) cells and in the central nervous system, but not in skeletal muscle or aorta tissues. The α_{1B-1} subunit directs the recombinant expression of N-type calcium channel activity when it is transiently co-expressed with human neuronal β_2 and α_{2B} subunits in mammalian HEK293 cells. The recombinant channel was irreversibly blocked by ω -CgTx but was insensitive to dihydropyridines. The $\alpha_{1B-1}\alpha_{2B}\beta_2$ -transfected cells displayed a single class of saturable, high-affinity (dissociation constant = 55 pM) ω -CgTx binding sites. Co-expression of the β_2 subunit was necessary for N-type channel activity, whereas the α_{2B} subunit appeared to modulate the expression of the channel. The heterogeneity of α_{1B} subunits, along with the heterogeneity of α_2 and β subunits, is consistent with multiple, biophysically distinct N-type calcium channels.

Voltage-dependent Ca^{2+} channels are multisubunit complexes through which extracellular Ca^{2+} enters excitable cells. In rabbit skeletal muscle, four tightly coupled subunits, α_1 , α_2 , β , and γ , make up the channel complex (1). The primary structure of each subunit has been determined and α_1 , α_2 , and β cDNAs have been used to characterize transcripts expressed in other tissues (2). The α_1 and β subunits are each encoded by a gene family, including at

least five distinct genes for α_1 subunits and three genes for β subunits (3-6). Primary transcripts of each of the α_1 genes, the α_2 gene, and two of the β genes have been shown to yield multiple, structurally distinct, subunits by means of differential processing (6-9). Expression studies have shown that the α_1 subunit forms the pore through which Ca^{2+} enters the cell (10, 11).

On the basis of biophysical and pharmacological characteristics, three subtypes of neuronal, high-voltage-activated Ca^{2+} channels (L-, N-, and P-type) have been proposed (2). These high-voltage-activated

SIBIA, Inc., 505 Coast Boulevard South, La Jolla, CA 92037.

*To whom correspondence should be addressed.




Fig. 1. Alignment of α_1 subunit deduced amino acid sequences. The nucleotide sequences have been deposited in GenBank (accession numbers M94172 and M94173 for α_{1B-1} and α_{1B-2} , respectively). The number of the amino acid residue at the end of each line is given. Abbreviations for the amino acid residues are: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr. Identical residues at one position in at least two of the sequences are enclosed in boxes. Potential N-glycosylation (o), cyclic adenosine monophosphate (AMP)-dependent phosphorylation (<), and protein kinase C phosphorylation

(>) sites (36) are shown. (A) Alignment of functional, neuronal α_1 subunits; the amino acid sequences of the human neuronal Ca^{2+} channel α_{1B-1} (1B-1), the human neuronal α_{1D} (1D) (8), and the rabbit brain BI-2 (1A-2) (11) are shown. BI-2 is designated 1A-2 because it is a rabbit homolog of the rat brain class A gene (4). The numbering begins with the proposed initiating methionine. The putative transmembrane segments S1 through S6 in each of the repeats I through IV are shown (brackets). (B) Alignment of α_{1B-1} and α_{1B-2} sequences through the region of the insertion-deletion (21). The deduced amino acid sequence of the 187-nt insertion (α_{1B-1} nt 6490 to 6676; Gly²¹⁶⁴ to Gly²²²⁶) is shown.

subtypes are most readily distinguished pharmacologically. The neuronal L-type channel is dihydropyridine (DHP)-sensitive and, in some cases, reversibly blocked by ω -conotoxin (ω -CgTx) (12, 13), the N-type channel is DHP-insensitive and irreversibly blocked by ω -CgTx (14), and the P-type channel is both DHP- and ω -CgTx-insensitive but is sensitive to toxins in venom from funnel web spiders (15). Recently, recombinant expression of neuronal Ca^{2+} channels was used to identify a high-voltage-activated, DHP-sensitive Ca^{2+}

channel that was reversibly blocked by ω -CgTx (classified as an L-type channel) (8) and a DHP-, ω -CgTx-insensitive Ca^{2+} channel (possibly a P-type channel) (11). Co-expression of α_1 and β subunits is necessary for substantial functional expression of both Ca^{2+} channel subtypes, whereas addition of an α_2 subunit increases the magnitude of the functional response.

Much evidence indicates that DHP-insensitive N-type Ca^{2+} channels that are irreversibly blocked by ω -CgTx are responsible for the voltage-activated release of

neurotransmitters in many neurons (16). In addition, ω -CgTx binding sites have been localized to the frog neuromuscular presynaptic membrane (17) and to organized, single clusters coincident with synaptic contact sites in hippocampal neurons (18). Furthermore, ω -CgTx binding sites on the presynaptic membrane of the frog neuromuscular terminal align precisely with active zones where vesicular exocytosis of neurotransmitters occurs (16, 17). Finally, ω -CgTx irreversibly blocks Ca^{2+} currents recorded directly from presynaptic termi-

nals (19). We report here the complete amino acid sequence of a human neuronal α_1 subunit (designated α_{1B}) that mediates N-type voltage-dependent Ca^{2+} channel activity, which is irreversibly blocked by ω -CgTx when transiently co-expressed with the human neuronal α_{2B} and β_2 subunits (8) in human embryonic kidney (HEK) 293 cells. The transfected cells bind ω -CgTx with high affinity.

We previously reported the isolation of cDNAs that encode the α_1 subunit of the rabbit skeletal muscle DHP-sensitive, L-type Ca^{2+} channel (3). These cDNAs were used as probes to isolate overlapping cDNAs encoding a complete human neuronal α_{1B} subunit (20). The translation initiation site was assigned to the first in-frame methionine codon, and no upstream in-frame nonsense codon was identified (Fig. 1A). Two isoforms of α_{1B} , α_{1B-1} and α_{1B-2} , that differ at their COOH-termini were identified (Fig. 1B). The α_{1B-1} subunit is comprised of 2339 amino acids and yields a calculated molecular weight of 262,494, whereas the α_{1B-2} subunit is comprised of 2237 amino acids and yields a calculated molecular weight of 251,757. These isoforms were identified by polymerase chain reaction (PCR) analysis (21) and revealed a deletion that produces α_{1B-2} , which likely results from alternative selection of a splice acceptor. This insertion-deletion that produces different COOH-termini is similar to the processing of putative rabbit α_{1A} gene transcripts encoding the rabbit BI-1 and BI-2 isoforms that mediate DHP-, ω -CgTx-insensitive high-voltage-activated Ca^{2+} channel activity (11). The α_{1B} sequence is 94.5% identical to the previously reported 164-amino acid sequence deduced from a rat brain class B partial cDNA (4) and has the same transmembrane topology as described previously for other Ca^{2+} channel α_1 subunits (7).

The deduced amino acid sequences of two different neuronal α_1 subunits, the human α_{1D} (8) and the rabbit BI-2 (11), are shown aligned with the human α_{1B-1} sequence (Fig. 1A). The α_{1B-1} amino acid sequence is 64.1% and 43.0% identical to the BI-2 and α_{1D} sequences, respectively. The sequence identity is relatively well conserved through the four repeating domains, 72.6% and 50.7% for the α_{1B-1} /BI-2 and the α_{1B-1} / α_{1D} pairs, respectively. Both of the DHP-insensitive α_1 subunits, human neuronal α_{1B-1} and rabbit neuronal BI-2, have characteristic large putative cytoplasmic loops between the IIS6 and IIS1 transmembrane domains. PCR analysis performed on RNAs isolated from IMR32 cells and several human primary tissues with α_{1B-1} - and α_{1B-2} -specific oligonucleotides identified α_{1B-1} and α_{1B-2} transcripts in IMR32 cells and in each of the human

central nervous system (CNS) tissues tested, including hippocampus, habenula, and thalamus but not in human skeletal muscle or aorta tissues (22).

The transient expression of the human neuronal α_{1B-1} , α_{2B} , and β_2 (8) subunits was studied in HEK293 cells (23). Transfected cells were examined for inward Ba^{2+} currents (I_{Ba}) mediated by voltage-dependent Ca^{2+} channels (24). Cells cotransfected with the α_{1B-1} , α_{2B} , and β_2 cDNAs expressed high-voltage-activated Ca^{2+} channels (Fig. 2). I_{Ba} first appeared when the membrane was depolarized from a holding potential of -90 mV to -20 mV and peaked in magnitude at 10 mV. Thirty-nine of 95 cells (12 independent transfections) had I_{Ba} that ranged from 30 to 2700 pA, with a mean of 433 pA. The mean current density was 26 pA/pF, and the highest density was 150 pA/pF (25). The I_{Ba} typically increased by 2- to 20-fold during the first 5 min of recording. Repeated depolar-

izations during long recordings often revealed rundown of I_{Ba} usually not exceeding 20% within 10 min. I_{Ba} typically activated within 10 ms and inactivated with both a fast time constant ranging from 46 to 105 ms and a slow time constant ranging from 291 to 453 ms ($n = 3$). Inactivation showed a complex voltage dependence, such that I_{Ba} elicited at ≥ 20 mV inactivated more slowly than I_{Ba} elicited at lower test voltages, possibly a result of an increase in the magnitude of slow compared to fast inactivation components at higher test voltages.

Recombinant $\alpha_{1B-1}\alpha_{2B}\beta_2$ channels were sensitive to holding potential (Fig. 3). Steady-state inactivation of I_{Ba} , measured after a 30- to 60-s conditioning at various holding potentials, was approximately 50% at holding potentials between -60 and -70 mV and approximately 90% at -40 mV. Recovery of I_{Ba} from inactivation was usually incomplete, measuring 55 to 75% of the original magnitude within 1 min after the holding potential was returned to more negative potentials, possibly indicating some rundown or a slow recovery rate.

Recombinant $\alpha_{1B-1}\alpha_{2B}\beta_2$ channels were also blocked irreversibly by ω -CgTx concentrations ranging from 0.5 to 10 μM during the time scale of the experiments (Fig. 4). Application of 5 μM toxin ($n = 7$) blocked the activity completely within 2 min, and we observed no recovery of I_{Ba} after washing ω -CgTx from the bath for up to 15 min. Cd^{2+} blockage (50 μM) was rapid, complete, and reversible; the DHPs Bay K 8644 (1 μM ; $n = 4$) or nifedipine (5 μM ; $n = 3$) had no discernable effect.

Cells cotransfected with cDNAs encoding α_{1B-1} , α_{2B} , and β_2 subunits predominantly displayed a single class of saturable, high-affinity ω -CgTx binding sites (26) (Fig. 5). The determined dissociation constant (K_d) value (Fig. 5) was 54.6 ± 14.5 pM ($n = 4$). Cells transfected with the vector containing only β -galactosidase cDNA or $\alpha_{2B}\beta_2$ cDNA showed no specific binding. The binding capacity (B_{max}) of the $\alpha_{1B-1}\alpha_{2B}\beta_2$ -transfected cells was $28,710 \pm 11,950$ sites per cell ($n = 4$).

These results demonstrate that $\alpha_{1B-1}\alpha_{2B}\beta_2$ -transfected cells express high-voltage-activated, inactivating Ca^{2+} channel activity that is irreversibly blocked by ω -CgTx, insensitive to DHPs, and sensitive to holding potential. The activation and inactivation kinetics and voltage sensitivity of the channel formed in these cells are generally consistent with previous characterizations of neuronal N-type Ca^{2+} channels (27, 28). Furthermore, the K_d value determined for ω -CgTx binding is in agreement with previously reported values (29).

The binding characteristics of ω -CgTx to HEK293 cells transiently expressing various subunit combinations were determined




Fig. 2. Voltage dependence and kinetics of I_{Ba} expressed in HEK293 cells transfected with α_{1B-1} , α_{2B} , and β_2 cDNAs (23). (A) Family of currents evoked at test voltages from -30 to 60 mV, from a holding potential of -90 mV. (B) Peak current-voltage relations measured from the currents in (A).




Fig. 3. Holding potential sensitivity of I_{Ba} expressed in HEK293 cells transfected with α_{1B-1} , α_{2B} , and β_2 cDNAs (23). Peak current-voltage (I - V) relations measured from voltage steps delivered from different holding potentials (-90 mV, \square ; -70 mV, \circ ; -50 mV, Δ ; return to -90 mV, ∇).

from saturation binding analysis (Table 1). Each recombinant cell type displayed a single class of binding sites similar to the $\alpha_{1B-1}\alpha_{2b}\beta_2$ -transfected cells, with K_d values ranging from 38.8 ± 13.1 pM to 76.1 ± 15.5 pM. The binding affinity of the recombinant cell types for ω -CgTx agrees well with that determined for intact IMR32 cells (36.5 ± 6.2 pM) (Table 1) but is different from measurements derived from crude homogenates of IMR32 cells (30).

There were significant differences in the receptor densities of the four recombinant cell types (Table 1). The B_{max} for ω -CgTx binding in $\alpha_{1B-1}\alpha_{2b}\beta_2$ -type cells was approximately ten times greater than that in $\alpha_{1B-1}\alpha_{2b}$ - and α_{1B-1} -type cells. The estimate for the binding capacity of the IMR32 cells correlates well with a previous report (30). The comparison of the B_{max} values suggests that the ω -CgTx-binding α_{1B-1} subunit is more efficiently expressed on the cell surface when co-expressed with the α_{2b} and β_2 subunits. Similarly, efficient expression of heteromeric protein complexes on the cell surface, such as nicotinic acetylcholine receptors, has been shown to require subunit assembly (31).

We performed whole cell recordings of HEK293 cells transfected with the cDNA encoding α_{1B-1} or with cDNAs encoding α_{1B-1} and α_{2b} or β_2 to assess functional contributions of the various subunits to the N-type channel activity. Currents recorded from $\alpha_{1B-1}\beta_2$ -transfected cells were observed at a frequency comparable to that of the $\alpha_{1B-1}\alpha_{2b}\beta_2$ -transfected cells (16 of 46 cells; five independent transfections), consistent with a B_{max} of approximately 12,000 receptors per cell (Table 1). These currents resembled those observed in $\alpha_{1B-1}\alpha_{2b}\beta_2$ -transfected cells, having similar current-voltage (*I-V*) curves, inactivation kinetics, and sensitivity to holding potential. Furthermore, $\alpha_{1B-1}\beta_2$ -mediated currents were irreversibly blocked by ω -CgTx (5 μ M; $n = 3$). However, currents in $\alpha_{1B-1}\beta_2$ -transfected cells were generally smaller in magnitude than those observed in $\alpha_{1B-1}\alpha_{2b}\beta_2$ cells and never exceeded 205 pA (15 pA/pF), with a mean of 91 pA (5.6 pA/pF). In contrast, currents in $\alpha_{1B-1}\alpha_{2b}\beta_2$ -transfected cells exceeded 200 pA in 57% of the cells tested (25).

Of 23 cells studied that were transfected with only α_{1B-1} (three independent transfections), two had small (20 to 40 pA) rapidly inactivating ($\tau = \sim 20$ ms) currents that were reversibly blocked by ω -CgTx. A similar current was detected in 1 of 11 $\alpha_{1B-1}\alpha_{2b}$ -transfected cells, whereas none of the untransfected HEK293 cells ($n = 17$) or HEK293 cells transiently expressing the α_{2b} and β_2 subunits ($n = 17$) displayed such currents. These results together with the relatively small B_{max} values observed in

α_{1B-1} -only and $\alpha_{1B-1}\alpha_{2b}$ -transfected cells (< 2650 receptors per cell) further support the importance of the β subunit in the formation of functional N-type Ca^{2+} channels.

N-type Ca^{2+} channels characterized from different cell preparations have biophysically distinct properties that have made it difficult to distinguish N- and




Fig. 4. Effect of ω -CgTx on I_{Ba} expressed in HEK293 cells transfected with α_{1B-1} , α_{2b} , and β_2 cDNAs (23). (A) Plot of peak current magnitude versus time before, during (hatched bar), and after (open bar) application of 5 μ M ω -CgTx. Test pulses (10 mV; holding potential = -90 mV) were delivered every 15 s before and during toxin application. Pulses were resumed every 30 s after recording of current-voltage relations from which only the current measured at 10 mV is shown. Similar results were obtained with the three concentrations of ω -CgTx tested: 0.5 μ M ($n = 3$), 5 μ M ($n = 7$), and 10 μ M ($n = 6$). (B) Example recordings made at points 1 to 4 of (A).




Fig. 5. Binding of ^{125}I - ω -CgTx. HEK293 cells were cotransfected with the α_{1B-1} , α_{2b} , and β_2 cDNAs (23) and assayed for specific binding of ^{125}I - ω -CgTx as a function of increasing concentration of ^{125}I - ω -CgTx (26); 2×10^5 cells were used in the assay mixture. (Inset) Scatchard analysis of the data. B, bound; F, free.

L-type currents on the basis of inactivation properties. N-type Ca^{2+} channels were first described in chicken sensory neurons as high-voltage-activated Ca^{2+} channels that could be activated only from strongly negative holding potentials and inactivated within tens of milliseconds (27). Current remaining after decay of the inactivating component or currents activated from holding potentials ≥ -40 mV were believed to represent L-type channel activity. N-type Ca^{2+} channels have since been found to inactivate slowly and incompletely in some neuronal types (32). The range of inactivation rates observed in different tissues may be a result of a combination of factors, including distinct combinations of variant channel subunits and different states of regulation. Recent single channel analysis indicates that individual N-type channels can switch between transient and long-lasting modes of gating (33). Our whole cell data that show biphasic decay of a recombinantly expressed N-type Ca^{2+} channel are consistent with a population of channels that exhibit different gating modes.

Recent biochemical studies on brain ω -CgTx receptors have revealed proteins on SDS-polyacrylamide gel electrophoresis of a relative molecular mass consistent with α_1 , α_2 , and β subunits (29), although additional uncharacterized bands were also observed. Molecular biological evidence indicates that multiple α_1 , α_2 , and β transcripts, including α_{1B} , α_{2b} , and β_2 mRNAs, are co-expressed in IMR32 cells and hippocampal tissue (8), both sources of ω -CgTx binding sites (18, 30). The recombinant expression of α_{1B-1} , α_{2b} , and β_2 subunits to produce ω -CgTx-sensitive N-type channel activity confirms that an α_{1B} gene product mediates this activity. The functional necessity of a β subunit and modulation by an

Table 1. Summary of Scatchard analysis of ω -CgTx binding to intact cells. HEK293 cells transfected with the indicated subunit cDNAs and IMR32 cells induced with dibutyl cyclic AMP and bromodeoxyuridine (28) were assayed for saturation of specific ω -CgTx binding, and the data were analyzed by the Scatchard method (26). The B_{max} values determined from Scatchard analysis were corrected for transfection efficiency.

Cell line	K_d (pM)	B_{max} (sites/cell)
$\alpha_{1B-1}\alpha_{2b}\beta_2$	54.6 ± 14.5	$28,710 \pm 11,950$ ($n = 4$)
$\alpha_{1B-1}\beta_2$	38.8 ± 13.1	$11,860 \pm 5,910$ ($n = 4$)
$\alpha_{1B-1}\alpha_{2b}$	76.1 ± 15.5	$2,650 \pm 620$ ($n = 4$)
α_{1B-1}	59.1 ± 15.5	$2,085 \pm 880$ ($n = 4$)
IMR32	36.5 ± 6.2	$6,770 \pm 615$ ($n = 2$)

α_2 subunit are consistent with the recombinant functional expression of other α_1 subtypes (8, 11), although expression of α_{1B-1} alone appears sufficient for ω -CgTx binding.

Our results suggest that multiple subtypes of the N-type channel might exist as a result of the heterogeneity of the subunits that comprise the channel complex. Co-expression of three different β gene products with the rabbit cardiac (α_{1C}) subunit alters the channel properties and thus indicates that subunit composition can determine distinct, voltage-dependent Ca^{2+} channels (6). At least two forms each of α_{1B} , α_2 , and β transcripts expressed in the brain are products of differential processing (6, 8, 34). This heterogeneity of the α_{1B} , α_2 , and β subunits is consistent with biophysically distinct N-type channels characterized from different cell preparations. Recombinant expression of each of the α_{1B} , α_2 , and β forms might reveal multiple N-type channels and the functional consequence of various subunit combinations (35).

REFERENCES AND NOTES

- K. P. Campbell, A. T. Leung, A. H. Sharp, *Trends Neurosci.* 11, 425 (1988).
- R. J. Miller, *J. Biol. Chem.* 267, 1403 (1992).
- S. B. Ellis *et al.*, *Science* 241, 1661 (1988).
- T. P. Snutch, J. P. Leonard, M. M. Gilbert, H. A. Lester, N. Davidson, *Proc. Natl. Acad. Sci. U.S.A.* 87, 3391 (1990); T. V. B. Starr, W. Prystay, T. P. Snutch, *ibid.* 88, 5621 (1991).
- E. Perez-Reyes *et al.*, *J. Biol. Chem.* 267, 1792 (1992).
- R. Hulin *et al.*, *EMBO J.* 11, 885 (1992).
- R. W. Tsien, P. T. Ellinor, W. A. Horne, *Trends Pharmacol. Sci.* 12, 349 (1991).
- M. E. Williams *et al.*, *Neuron* 8, 71 (1992).
- M. Pragnell, J. Sakamoto, S. D. Jay, K. P. Campbell, *FEBS Lett.* 291, 253 (1991).
- A. Mikami *et al.*, *Nature* 340, 230 (1989).
- Y. Mori *et al.*, *ibid.* 350, 398 (1991).
- T. Aosaki and H. Kasai, *Pfluegers Arch.* 414, 150 (1989).
- D. Swandulla, E. Carbone, H. D. Lux, *Trends Neurosci.* 14, 46 (1991).
- E. Sher and F. Clementi, *Neuroscience* 42, 301 (1991).
- R. Llinás, M. Sugimori, J. W. Lin, B. Cherksey, *Proc. Natl. Acad. Sci. U.S.A.* 86, 1689 (1989); I. M. Mintz *et al.*, *Nature* 355, 827 (1992).
- S. J. Smith and G. J. Augustine, *Trends Neurosci.* 11, 458 (1988).
- R. Robitaille, E. M. Adler, M. P. Charlton, *Neuron* 5, 773 (1990); M. W. Cohen, O. T. Jones, K. J. Angelides, *J. Neurosci.* 11, 1032 (1991); F. T. Tarelli, M. Passafaro, F. Clementi, E. Sher, *Brain Res.* 547, 331 (1991).
- O. T. Jones, D. L. Kunze, K. J. Angelides, *Science* 244, 1189 (1989).
- E. F. Stanley and G. Göping, *J. Neurosci.* 11, 985 (1991).
- Recombinant cDNA libraries were prepared, and overlapping α_{1B-1} cDNA clones were isolated from IMR32, human hippocampus, and basal ganglia cDNA libraries and characterized essentially as described (3, 8).
- We performed PCR analyses as described (8) using IMR32 RNA, human hippocampus RNA, and human genomic DNA with α_{1B-1} -specific primers [nucleotides (nt) 6368 to 6391 and the complement of nt 7071 to 7095] to confirm the α_{1B} termination codon. The RNAs gave the expected 728-bp fragment (α_{1B-1}) as well as a 541-bp fragment (α_{1B-2}). The genomic DNA product was ~1350 bp. The DNA sequences of α_{1B-1} and α_{1B-2} diverge from each other after nt 6489. The α_{1B-1} subunit contains an additional 187-bp exon that alters the reading frame. After this exon, the α_{1B-1} and α_{1B-2} sequences are identical for the remaining 419 nucleotides characterized from both sequences, α_{1B-1} nt 6677 to 7095 and α_{1B-2} nt 6490 to 6908. The presence of the exon (α_{1B-1}) results in the termination of the coding sequence at nt 7018 to 7020 (TAG); the absence of the exon (α_{1B-2}) results in the termination of the coding sequence at nt 6712 to 6714 (TGA). Differential processing of the α_{1B} primary transcript was confirmed by characterization of the α_{1B} genomic PCR product. An ~270-bp intron was identified between α_{1B-1} nt 6489 and 6490. The α_{1B-1} and α_{1B-2} transcripts result from alternative selection of splice acceptor sites. α_{1B-1} is formed by selection of the splice acceptor at the intron-exon boundary, at nt 6490 on the exon side of the boundary; α_{1B-2} is formed by selection of a splice acceptor identified by an AG dinucleotide at nt 6675 and 6676 of the α_{1B-1} coding sequence.
- Tissue distribution of the α_{1B-1} and α_{1B-2} transcripts was determined by PCR assays with oligonucleotide primers, nt 6447 to 6470 (Pro²¹⁴⁹ to Glu²¹⁵⁷), and the complement of α_{1B-1} -specific nt 6819 to 6843 (Leu²²⁷³ to Glu²²⁸¹). PCR products were probed with an α_{1B-1} -specific oligonucleotide (nt 6513 to 6536; Ser²¹⁷¹ to Ala²¹⁷⁹) and an α_{1B-2} -specific oligonucleotide (nt 6480 to 6498; Pro²¹⁶⁰ to Ser²¹⁶⁹). The expected size bands were 396 bp (α_{1B-1}) and 209 bp (α_{1B-2}).
- pcDNA α_{1B-1} was constructed in pcDNA1 (Invitrogen, San Diego, CA) with $\alpha_{1.179}$ (nt -143 to 2194), $\alpha_{1.177}$ (nt 2194 to 4160), $\alpha_{1.201}$ (nt 4160 to 5305), $\alpha_{1.200}$ (nt 5305 to 6116), and $\alpha_{1.230}$ (nt 6116 to 7176). DNA sequence analysis revealed that $\alpha_{1.177}$ has a two-nucleotide deletion (nt 3711 to 3712; Ser¹²³⁷) that was corrected with a PCR-amplified IMR32 Nar I-Kpn I fragment (nt 3685 to 4160; Gly¹²²⁹ to Gly¹³⁸⁷). pHBcCaCh α_{2B} (A) and pHBcCaCh β_{2B} -RBS(A), full-length α_{2B} and β_{2B} constructs in pcDNA1, were described previously (8). HEK293 cells [B. W. Stillman and Y. Gluzman, *Mol. Cell. Biol.* 5, 2051 (1985)] were grown as a monolayer culture in Dulbecco's modified Eagle's medium (Gibco) containing 5% defined-supplemented bovine calf serum (Hyclone) plus penicillin G (100 U/ml) and streptomycin sulfate (100 μ g/ml). HEK293 cell transfections were mediated by calcium phosphate [F. M. Ausubel *et al.*, Eds., *Current Protocols in Molecular Biology* (Wiley, New York, 1990), pp. 9.1.1 to 9.1.7]. Cells were transfected (2×10^6 per polylysine-coated plate). Standard transfections (10-cm dish) contained 8 μ g of pcDNA α_{1B-1} , 5 μ g of pHBcCaCh α_{2B} (A), 2 μ g of pHBcCaCh β_{2B} -RBS(A), 2 μ g of pCMV β (Clontech β -galactosidase expression plasmid), and pUC18 to maintain a constant mass of 20 μ g/ml. Cells were analyzed 48 to 72 hours after transfection. Transfection efficiencies ($\pm 10\%$) were determined by in situ histochemical staining for β -galactosidase activity [J. R. Sanes, J. L. R. Rubenstein, J.-F. Nicolas, *EMBO J.* 5, 3133 (1986)]. Transfection efficiencies generally were $>50\%$.
- Properties of recombinantly expressed Ca^{2+} channels were studied by whole cell patch-clamp techniques [O. P. Hamill, A. Marty, E. Neher, B. Sakmann, F. J. Sigworth, *Pfluegers Arch.* 391, 85 (1981)]. Recordings were performed on transfected HEK293 cells 2 to 3 days after transfection. Cells were plated at 100,000 to 300,000 cells per polylysine-coated, 35-mm tissue culture dishes (Falcon, Oxnard, CA) 24 hours before recordings. Cells were perfused with 15 mM BaCl₂, 125 mM choline chloride, 1 mM MgCl₂, and 10 mM Hepes (pH = 7.3) adjusted with tetraethylammonium hydroxide (bath solution). Pipettes were filled with 135 mM CsCl, 10 mM EGTA, 10 mM Hepes, 4 mM Mg-adenosine triphosphate (pH = 7.5) adjusted with tetraethylammonium hydroxide. Sylgard (Dow-Corning, Midland, MI)-coated, fire-polished, and filled pipettes had resistances of 1 to 2 megohm before we established gigaohm seals to cells. ω -CgTx (Bachem, Bay K 8644, and nifedipine (Research Biochemicals, Natick, MA) were prepared as described (8), dissolved in bath solution, and continuously applied by means of puffer pipettes as required for a given experiment. Recordings were performed at room temperature (22° to 25°C). Series resistance compensation (70 to 85%) was employed to minimize voltage error that resulted from pipette access resistance, typically 2 to 3.5 megohm. Current signals were filtered (-3 dB, 4-pole Bessel) at a frequency of 1/4 to 1/5 the sampling rate, which ranged from 0.5 to 3 kHz. Voltage commands were generated, and data were acquired with CLAMPX (pClamp, Axon Instruments, Foster City, CA). All data shown are corrected for linear leak and capacitive components as described (8). Exponential fitting of currents was performed with CLAMPFIT (Axon).
- Currents <30 pA were not included because of unreliable measurements. For $\alpha_{1B-1}\alpha_{2B}\beta_{2B}$ -transfected cells, currents in 43.6% of the expressing cells ranged from 30 to 200 pA, 43.6% of the cells had currents that ranged from 200 to 1000 pA, and 12.8% had currents that exceeded 1000 pA.
- We mechanically removed cells from tissue culture plates 48 hours after transfection by spraying with phosphate-buffered saline that contained 0.1% (w/v) bovine serum albumin (BSA). The cells were collected, washed once, and resuspended in assay buffer [10 mM Hepes (pH 7.4), 140 mM NaCl, 5 mM KCl, 12 mM glucose, and BSA (1 mg/ml)]. Specific binding of ¹²⁵I- ω -CgTx to transfected cells was determined as described (30) with several modifications. Briefly, we performed the assay in 12 mm x 75 mm polypropylene tubes in 0.5 ml of assay buffer by incubating the cells with 100 pM ¹²⁵I- ω -CgTx (DuPont Biotechnology Systems; 2200 Ci/mmol) for 1 hour at 37°C. Subsequently, 2 ml of ice-cold wash buffer [5 mM Hepes (pH 7.4), 160 mM choline chloride, 1.5 mM CaCl₂, and BSA (1 mg/ml)] was added to each tube, and the mixtures were centrifuged at 2300g for 30 min at 4°C. The pellets were washed again and counted for radioactivity. Nonspecific binding was determined in the presence of 20 nM unlabeled ω -CgTx. The optimum cell number was determined by a titration of 1×10^5 to 2×10^6 cells per assay tube. For saturation binding studies, the binding of ¹²⁵I- ω -CgTx was measured as a function of increasing concentration of ¹²⁵I- ω -CgTx. Nonspecific binding was subtracted at each concentration. Specific binding was plotted as a function of ¹²⁵I- ω -CgTx concentration and analyzed by the Scatchard method.
- M. C. Nowycky, A. P. Fox, R. W. Tsien, *Nature* 316, 440 (1985); A. P. Fox, M. C. Nowycky, R. W. Tsien, *J. Physiol. (London)* 394, 149 (1987).
- E. Carbone, E. Sher, F. Clementi, *Pfluegers Arch.* 416, 170 (1990).
- J. A. Wagner, A. M. Snowman, A. Biswas, B. M. Olivera, S. H. Snyder, *J. Neurosci.* 8, 3354 (1988); J. Sakamoto and K. P. Campbell, *J. Biol. Chem.* 266, 18914 (1991); M. K. Ahlman, J. Striessnig, W. A. Catterall, *ibid.*, p. 20192; M. W. McEnery, A. M. Snowman, A. H. Sharp, M. E. Adams, S. H. Snyder, *Proc. Natl. Acad. Sci. U.S.A.* 88, 11095 (1991).
- E. Sher, A. Pandiella, F. Clementi, *FEBS Lett.* 235, 178 (1988).
- P. Blount, M. M. Smith, J. P. Mertie, *J. Cell Biol.* 111, 2601 (1990).
- M. R. Plummer, D. E. Logothetis, P. Hess, *Neuron* 2, 1453 (1989); S. W. Jones and T. N. Marks, *J. Gen. Physiol.* 94, 169 (1989).
- M. R. Plummer and P. Hess, *Nature* 351, 657 (1991).
- H.-L. Kim, H. Kim, P. Lee, R. G. King, H. Chin, *Proc. Natl. Acad. Sci. U.S.A.* 89, 3251 (1992).
- The amino acid sequence of a rat α_1 subunit, rbB-1, has been reported [S. J. Dubel *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89, 5058 (1992)] and is 92.8% identical to that of the human α_{1B-1} subunit. However, attempts to express the cDNA encoding the rbB-1 protein did not yield functional Ca^{2+} channels, thus supporting our conclusion that additional subunits, such as β_2 and α_{2B} , are

- required for functional expression.
36. E. Bause, *Biochem. J.* 209, 331 (1983); D. B. Glass, M. R. El-Maghrabi, S. J. Pilgis, *J. Biol. Chem.* 261, 2987 (1986); J. R. Woodgett, K. L. Gould, T. Hunter, *Eur. J. Biochem.* 161, 177 (1986).
37. We thank K. Payne for thoughtful secretarial as-

sistance, G. Holtz for computer assistance, and S. Wagner for providing CNS polyadenylated RNAs. We also thank V. Dionne, R. Evans, S. Heinemann, C. Liaw, R. Miller, P. Schoeneck, and S. Wagner for helpful discussions regarding this work.

15 May 1992; accepted 11 June 1992

Membrane Depolarization Induces p140^{Trk} and NGF Responsiveness, But Not p75^{NGFR}, in MAH Cells

Susan J. Birren, Joseph M. Verdi, David J. Anderson*

Nerve growth factor (NGF) is required for the maturation and survival of sympathetic neurons, but the mechanisms controlling expression of the NGF receptor in developing neuroblasts have not been defined. MAH cells, an immortalized sympathoadrenal progenitor cell line, did not respond to NGF and expressed neither low-affinity NGF receptor (p75) nor p140^{Trk} messenger RNAs. Depolarizing concentrations of potassium chloride, but none of a variety of growth factors, induced expression of p140^{Trk} but not p75 messenger RNA. A functional response to NGF was acquired by MAH cells under these conditions, suggesting that expression of p75 is not essential for this response. Depolarization also permitted a relatively high proportion of MAH cells to develop and survive as neurons in fibroblast growth factor and NGF. These data establish a relation between electrical activity and neurotrophic factor responsiveness in developing neurons, which may operate in the functioning of the mature nervous system as well.

The survival of vertebrate neurons is dependent on neurotrophic factors secreted by their postsynaptic targets. NGF, the prototypic neurotrophic factor, is required for the survival of sympathetic and some sensory neurons (1). The embryonic precursors to sympathetic neurons neither respond to nor require NGF (2–4). This raises the question of how developing sympathetic neuroblasts acquire their responsiveness to and dependence on NGF. We have studied this process with the use of MAH cells a retrovirally immortalized sympathoadrenal progenitor cell line (5). The identification of the product of the proto-oncogene *trk*, p140^{Trk} (Trk), as a signal-transducing subunit of the NGF receptor (NGFR) (6, 7) has allowed us to use Trk mRNA expression to assay environmental signals that may induce NGF responsiveness in MAH cells. Here we identify membrane depolarization as one such signal.

MAH cells, like the nonimmortalized progenitors from which they derive, do not undergo neuronal differentiation in response to NGF. The protein p75, the low-affinity NGFR (8, 9), is not expressed by these cells (5). MAH cells grown in the absence of added factors also express little or no Trk mRNA (Fig. 1A, lanes 1 and 2). Thus, the failure of these precursor cells to respond to NGF correlates with their lack

of expression of both types of NGFR mRNAs. We then sought to identify factors that induce expression of NGFR and NGF responsiveness. Previously, we found that basic fibroblast growth factor (bFGF) induced low levels of p75 expression and NGF responsiveness in a small subpopulation of MAH cells (5). However, bFGF failed to induce significant Trk expression in MAH cells, as did a number of other growth and neurotrophic factors (Fig. 1A, lanes 4 through 7, and data not shown). In addition, retinoic acid, which induces high-affinity NGF receptors and NGF dependence in chick sympathetic neuroblasts (10), did not induce Trk mRNA (Fig. 1A, lane 8).

In the chick, depolarization increases the survival of NGF-dependent sympathetic neurons (4). In MAH cells, depolarization stimulated the survival of postmitotic neurons. Depolarization of MAH cells produced by the addition of 40 mM KCl led to an induction of Trk mRNA (Fig. 1A, lane 3). A time course in 40 mM KCl revealed that Trk expression was detectable within 24 hours and reached maximal amounts within 3 days (Fig. 1C, lanes 5 through 8). Reprobing of the same blots with p75 probes revealed that, in contrast to Trk mRNA, p75 mRNA was not induced by 40 mM KCl.

MAH cells require dexamethasone (dex) for long-term survival; when dex is removed, the cells die within 4 to 5 days. In the presence of 5 μ M dex, a low steady-state amount of Trk mRNA was detected (Fig. 1B, lane 2). However, even in the

presence of dex an up-regulation of Trk mRNA by 40 mM KCl occurred (Fig. 1B, lane 3), indicating that the effect of depolarization is not simply to maintain the survival of Trk-expressing MAH cells. The time course of Trk induction by 40 mM KCl was similar in the presence of dex (Fig. 1D, lanes 6 through 9) as in its absence, although higher steady-state amounts of Trk mRNA were produced in the presence of dex (compare Fig. 1D, lane 8, with Fig. 1C, lane 7). As was the case in the absence of dex, no induction of p75 mRNA was detected in 40 mM KCl plus dex.

The effect of 40 mM KCl is likely to be produced by membrane depolarization because no induction of Trk mRNA was observed in 40 mM NaCl (Fig. 1, A and B, lanes 9). Moreover, veratridine, an Na⁺ channel agonist that leads to membrane depolarization, also caused an increase in the amount of Trk mRNA concentrations (data not shown). In PC12 cells, the induction of immediate-early gene expression by membrane depolarization requires the opening of voltage-gated Ca²⁺ channels and depends on extracellular Ca²⁺ (11). Removal of extracellular Ca²⁺ or addition of dihydropyridine antagonists of voltage-gated Ca²⁺ channels resulted in the death of MAH cells within 24 hours, precluding our ability to determine a requirement for Ca²⁺ influx in Trk induction. However, at suboptimal concentrations of KCl (20 mM) (Fig. 1E, lane 4), the Ca²⁺ channel agonist Bay K 8644 potentiated the induction of Trk mRNA (Fig. 1F, lanes 3 and 4), which suggests that Ca²⁺ influx through voltage-gated L-type Ca²⁺ channels is indeed involved in the induction of Trk mRNA by membrane depolarization.

We then sought to determine whether depolarization induces a functional response to NGF. We used two assays of NGF responsiveness: neurite outgrowth and cell number. Cell number reflects both the survival- and proliferation-promoting (12) effects of NGF, although for technical reasons it is difficult to determine the relative contributions of these two processes in this system. NGF responses were assayed after 5 days, by which time most MAH cells had died in control medium (Table 1). Those few cells that survived showed little process outgrowth (Fig. 2A). Similar results were obtained in NGF alone (Fig. 2B and Table 1), indicating that MAH cells do not respond to this factor. Cell number was significantly increased by depolarizing concentrations of KCl (Table 1), although little neurite outgrowth was observed (Fig. 2C). In NGF plus 40 mM KCl, cell number was even higher (Table 1) and the cells bore long neurites (Fig. 2D). These neurite-bearing cells, however, lacked the cell soma hypertrophy characteristic of mature neu-

S. J. Birren, Division of Biology, California Institute of Technology, Pasadena, CA 91125.
J. M. Verdi and D. J. Anderson, Division of Biology and the Howard Hughes Medical Institute, California Institute of Technology, Pasadena, CA 91125.

*To whom correspondence should be addressed.

Structure and Functional Expression of α_1 , α_2 , and β Subunits of a Novel Human Neuronal Calcium Channel Subtype

Mark E. Williams, Daniel H. Feldman,
Ann F. McCue, Robert Brenner,*
Gonul Velicelebi, Steven B. Ellis,
and Michael M. Harpold
The Salk Institute Biotechnology/Industrial
Associates, Inc.
505 Coast Boulevard South
La Jolla, California 92037

Summary

The primary structures of human neuronal α_1 , α_2 , and β subunits of a voltage-dependent Ca^{2+} channel were deduced by characterizing cDNAs. The α_1 subunit (α_{1D}) directs the recombinant expression of a dihydropyridine-sensitive L-type Ca^{2+} channel when coexpressed with the β (β_2) and the α_2 (α_{2D}) subunits in *Xenopus* oocytes. The recombinant channel is also reversibly blocked by 10–15 μM ω -conotoxin. Expression of the α_{1D} subunit alone, or coexpression with the α_{2D} subunit, did not elicit functional Ca^{2+} channel activity. Thus, the β_2 subunit appears to serve an obligatory function, whereas the α_{2D} subunit appears to play an accessory role that potentiates expression of the channel. The primary transcripts encoding the α_{1D} , α_2 , and β subunits are differentially processed. At least two forms of neuronal α_{1D} were identified. Different forms of α_2 and β transcripts were also identified in CNS, skeletal muscle, and aorta tissues.

Introduction

The primary pathway by which Ca^{2+} enters excitable cells is through voltage-dependent Ca^{2+} channels present in cellular membranes (Bean, 1989). Multiple subtypes of these channels have been identified (Hess, 1990), the best characterized of which is the rabbit skeletal muscle dihydropyridine (DHP)-sensitive Ca^{2+} channel, consisting of four tightly coupled subunits, α_1 , α_2 , β , and γ (Campbell et al., 1988). Each of these subunits has been characterized by cDNA cloning (Tanabe et al., 1987; Ellis et al., 1988; Ruth et al., 1989; Jay et al., 1990). Recent evidence suggests that different α_1 subunits are encoded by a gene family comprising at least five distinct genes, some of which are expressed in several tissues (Ellis et al., 1988; Mikami et al., 1989; Perez-Reyes et al., 1990; Snutch et al., 1990). The gene encoding the α_1 subunit expressed in rabbit skeletal muscle directs the recombinant expression of a functional DHP-sensitive Ca^{2+} channel in cultured myotubes of *mdg* mice and in mouse L cells (Tanabe et al., 1988; Perez-Reyes et al., 1989). A second gene, encoding α_1 subunits expressed in rabbit cardiac and lung tissues, directs the synthesis of

DHP-sensitive Ca^{2+} channels in *Xenopus* oocytes (Mikami et al., 1989; Biel et al., 1990). In contrast, a third α_1 subunit gene, expressed in rabbit brain, directs the synthesis of Ca^{2+} channels that are insensitive to both DHPs and ω -conotoxin GVIA (ω -CgTx) when coexpressed with the rabbit skeletal muscle α_2 and β subunits in *Xenopus* oocytes (Mori et al., 1991). These expression studies in oocytes demonstrated that the α_1 subunit forms the pore through which Ca^{2+} enters the cell. The functional expression of α_1 subunits encoded by the two remaining genes has not yet been reported.

The entry of Ca^{2+} through voltage-dependent Ca^{2+} channels in neurons controls diverse functions, such as neurotransmitter release, excitability, and differentiation (Tsien et al., 1988). On the basis of biophysical and pharmacological characterizations, four subtypes of neuronal voltage-dependent Ca^{2+} channels have been proposed (Llinás et al., 1989; Swandulla et al., 1991). Although specific neuronal functions have been ascribed to different Ca^{2+} channel subtypes, the analysis has been difficult due to the coexistence of multiple subtypes in individual cells (Miller, 1987; Bean, 1989; Hess, 1990; Swandulla et al., 1991). One important step in defining subtype-function relationships is the cloning and expression of each neuronal subtype as a pure population. We report the complete amino acid sequence and functional expression of three subunits of a human neuronal L-type voltage-dependent Ca^{2+} channel: an α_1 subunit (designated α_{1D}), an α_2 subunit (designated α_{2D}), and a β subunit (designated β_2). A description of the nomenclature used to designate the different Ca^{2+} channel subunits is provided in the Experimental Procedures. We also report tissue-specific processing of the α_2 and β transcripts.

Results

Cloning and Characterization of Three Human Neuronal Voltage-Dependent Ca^{2+} Channel Subunits

We previously reported the isolation of cDNAs that encode the α_1 , α_2 , β , and γ subunits of the rabbit skeletal muscle DHP-sensitive, L-type Ca^{2+} channel (Ellis et al., 1988; Jay et al., 1990). These subunit cDNAs were used as probes to isolate related human neuronal cDNAs as described in the Experimental Procedures. The primary structures of the human neuronal α_{1D} , α_{2D} , and β_2 subunits (Figure 1; see Figure 3 and Figure 4) were deduced from these cDNA sequences.

α_{1D} Subunit

The primary structure of the human α_{1D} subunit (Figure 1) comprises 2161 amino acids, yielding a calculated molecular weight of 245,163. The α_{1D} sequence is most similar (96.3% deduced amino acid sequence identity) to the previously reported 188 amino acid

*Present address: Department of Zoology, University of Texas, Austin, Texas 78712.



OCT 00 2003 4:00 AM

partial rat brain class D cDNA (Snutch et al., 1990). The translation initiation site was assigned to the first methionine codon that appears downstream of an in-frame nonsense codon. Interestingly, 7 methionine codons appear at the beginning of the putative coding sequence, followed by 2 lysine codons and an eighth methionine codon; none of these methionine codons are contained within the consensus sequence for eucaryotic initiation codons (Kozak, 1987). This series of methionine codons was confirmed by direct sequence analysis of cloned polymerase chain reaction (PCR) products derived from reactions performed on human neuroblastoma IMR32 cell cytoplasmic RNA, as described in the Experimental Procedures.

The predicted structure of the α_{10} subunit consists of four repeating domains, each domain comprised of five hydrophobic segments (S1, S2, S3, S5, and S6) and one positively charged segment (S4), suggesting the same transmembrane topology as described previously for Ca^{2+} channel α_1 subunits and Na^+ channels (Numa and Noda, 1986; Tanabe et al., 1987; Mikami et al., 1989; Biel et al., 1990; Koch et al., 1990; Mori et al., 1991). Based on this proposed topology, the α_{10} subunit has 3 of 12 potential N-glycosylation sites (Bause, 1983) assigned to the extracellular side and nine of ten potential cAMP-dependent phosphorylation sites (Glass et al., 1986) and 22 of 26 potential protein kinase C phosphorylation sites (Woodgett et al., 1986) assigned to the cytoplasmic side of the cellular membrane (Figure 2).

The α_{10} cDNA clone $\alpha 1.136$ was found to encode an incompletely processed transcript containing two exons encoding the I56 transmembrane domain, designated α_{10} exon A and α_{10} exon B. The deduced amino acid sequences are MNDAMGFELPWVYFVSLVIFGFFVLNLVLGVLSG and VNDAIGWEWPWVYFVSLIILGFFVLNLVLGVLSG, respectively, which share 83% identity. Exon A was present in clone $\alpha 1.144$, which was used for the construction of the full-length α_{10} cDNA used in the present study (Figure 1).

The deduced amino acid sequences of two different α_1 subunits, the rabbit cardiac (Mikami et al., 1989) and the rabbit brain BI-2 (Mori et al. 1991), previously expressed in *Xenopus* oocytes, are shown aligned with the human α_{10} sequence (Figure 2). The amino acid sequence identity of α_{10} to these sequences is significant: 70.3% and 40.5% for the cardiac and BI-2 sequences, respectively. The sequence identity is well conserved through the four repeating domains, 79.7% and 50.5% for the α_{10} -cardiac and the α_{10} -BI-2 pairs, respectively. Most noteworthy is the divergence of the α_{10} and cardiac sequences compared with the BI-2 sequence through the putative DHP-binding region (Regulla et al., 1991). In this region, the α_{10} and cardiac DHP-sensitive forms differ by a single amino acid (Ser-1490) as does the rabbit skeletal muscle sequence (Ala-1404), whereas the BI-2 DHP-insensitive form has 18 amino acid substitutions in this region (Figure 2). This evidence, together with the results of the expression studies reported here (see below), supports the proposed identity of the DHP-binding region.

α_{2b} Subunit

The primary structure of the human brain α_{2b} subunit (Figure 3) consists of 1091 amino acids, yielding a calculated molecular weight of 123,182. The amino acid sequence homology is 97.1% identical to the rabbit skeletal muscle α_{2a} subunit sequence (Figure 3) and has essentially an identical predicted topography and secondary structure (Ellis et al., 1988; Jay et al., 1991), with the exceptions of a 19 amino acid deletion in the human sequence compared with the rabbit sequence (α_{2a} residues Pro-507 to Gln-525) and a 7 amino acid insertion in the human sequence compared with the rabbit sequence (α_{2b} residues Lys-602 to Asp-608). The 16 potential glycosylation sites that were identified in the rabbit skeletal muscle α_{2a} subunit (Jay et al., 1991) also are conserved in the human α_{2b} sequence. Previous studies suggest that posttranslational processing of the rabbit skeletal α_{2a} subunit results in a heterogeneous population of 8 peptides, all of which begin at Ala-935 (Jay et al., 1991). The human brain α_{2b} sequence has two conservative amino acid substitutions at this proposed cleavage site, Val-923 and Glu-924 replacing Ala-935 and Asp-936, respectively (Figure 3).


β_1 and β_2 Subunits

The primary structure of the human brain β_2 subunit (Figure 4) comprises 478 amino acids and has a calculated molecular weight of 52,934. The amino acid sequence homology is 96.9% identical to the rabbit skeletal muscle β_1 subunit sequence (Figure 4). The β_2 subunit has essentially an identical topography and secondary structure as predicted for the rabbit skeletal muscle β_1 subunit (Ruth et al., 1989) except that the deduced human β_2 sequence has a deletion of 45 amino acids (Ala-217 to Lys-261). The lack of this region in β_2 removes the second α helical domain proposed for the rabbit skeletal muscle β_1 subunit (Ruth et al., 1989). Thirteen of sixteen potential phosphorylation sites identified in the rabbit skeletal muscle β_1 subunit (Ruth et al., 1989) are conserved in the human β_2 sequence (Figure 4). Two sites are changed due to amino acid substitutions (β_1 Ser-179 and Ser-182), and the third is removed by the 45 amino acid deletion (β_1 Ser-238).

Another form of β , designated β_3 , which has the same deduced 45 amino acid deletion, was identified in the hippocampus cDNA library. Clone $\lambda\beta 4$ encodes the β_3 cDNA and diverges from β_2 after nucleotide 1332. The β_3 cDNA extends another 429 nucleotides with no translation stop codon identified (data not shown). A GT splice donor is not present at the point of divergence between the β_2 and β_3 sequences. A complete characterization of β_3 is in progress.

Tissue-Specific Processing of the α_1 and β Transcripts and Distribution of α_{10} , α_{2a} , and β mRNAs

PCR analysis and hybridization with oligonucleotides derived from α_{2a} - or α_{2b} -specific regions (the 19 amino acid region or the 7 amino acid region, respectively; Figure 3) demonstrated that the human skeletal






Figure 3. Determined cDNA Sequence of α_{2b} and Alignment of the Deduced Amino Acid Sequence with the Deduced Rabbit Skeletal Muscle α_{2b} Sequence

For the rabbit α_{2b} sequence (Rab; Ellis et al., 1988), only the amino acid differences compared with the human α_{2b} sequence (Hum) are shown. The 5' untranslated sequence is negatively numbered. Positive numbering begins at the first nucleotide of the proposed initiating codon. The number of the nucleotide and amino acid residue is given at the end of each line. Negative numbers for amino acids designate residues contained in the proposed signal sequence (Ellis et al., 1988) beginning with the initiating methionine (-24 and -26). The positive numbering begins at the NH₂-terminal residue (glutamic acid) of the mature protein. Amino acid sequence differences and insertions/deletions are identified by the black boxes. Potential N-glycosylation (N), cAMP-dependent phosphorylation (<), and protein kinase C phosphorylation (>) sites are shown. The potential target of either kinase is labeled (+).

He

To confirm the tissue-specific processing of the β subunit primary transcript, β -specific PCR products of human skeletal muscle and aorta were cloned, and the DNA sequence was determined. The deduced human skeletal muscle amino acid sequence is 92% identical to the rabbit skeletal muscle sequence from position Gly-210 to Lys-261 (Figure 4). The β_2 sequence has a proposed alternative exon (Ala-210 to Ser-216) that

Oocytes coinjected with the α_{10} , α_{7b} , and β_2 mRNAs expressed sustained I_{Na} upon depolarization (162 ± 121 nA, $n = 46$) that typically showed little inactivation during test pulses ranging from 140–700 ms (Figure 6A). A series of voltage steps revealed currents that appeared at approximately -30 mV and peaked at approximately 0 mV (Figure 6B). Application of the DHP




Figure 4. Determined cDNA Sequence of β_1 and Alignment of the Deduced Amino Acid Sequence with the Deduced Rabbit Skeletal Muscle β_1 Sequence

For the rabbit β_1 sequence (Rab; Ruth et al., 1989), only the amino acid differences compared with the human β_1 sequence (Hum) are shown. See legend of Figure 3 for description of symbols and numbering.

Ca^{2+} channel agonist Bay K 8644 increased the magnitude of the $\alpha_{10}\alpha_{2b}\beta_2$ -mediated currents, prolonged the "tail" currents present upon repolarization of the cell, and induced a hyperpolarizing shift in current activation (Figures 6A and 6B). Application of the DHP Ca^{2+} channel antagonist nifedipine blocked a substantial fraction of the I_{Ba} in oocytes coinjected with α_{10} , α_{2b} , and β_2 (91% \pm 6%; $n = 7$; Figure 6C). Much of the I_{Ba} recovered when the holding potential was shifted from -50 mV to -90 mV (data not shown), consistent with the voltage-dependent block by nifedipine (Bean, 1984; Sanguinetti and Kass, 1984). A residual inactivating component of I_{Ba} typically remained after nifedipine application. Consistent with previous studies on neuronal L-type Ca^{2+} channels (Fox et al., 1987), the $\alpha_{10}\alpha_{2b}\beta_2$ -mediated I_{Ba} was blocked completely by $50 \mu\text{M}$ Cd^{2+} , but only approximately 15% by $100 \mu\text{M}$ Ni^{2+} .

The $\alpha_{10}\alpha_{2b}\beta_2$ -mediated I_{Ba} was blocked weakly (54% \pm 29%, $n = 7$) and reversibly by relatively high concentrations (10–15 μM) of $\omega\text{-CgTx}$ (Figure 6D). Bay K 8644 was first applied to the cell in order to determine the effect of $\omega\text{-CgTx}$ on the DHP-sensitive current component that was distinguished by the prolonged tail currents. Both the test currents and the accompanying tail currents were blocked progressively within 1–3 min after application of $\omega\text{-CgTx}$, but both recovered partially as the $\omega\text{-CgTx}$ was flushed from the bath.

The contribution of the α_{2b} and β_2 subunits to the $\alpha_{10}\alpha_{2b}\beta_2$ -mediated current was assayed by expression of the α_{10} subunit alone or in combination with either the β_2 subunit or the α_{2b} subunit. Oocytes injected with only the α_{10} mRNA produced no discernible I_{Ba} upon depolarization ($n = 10$). Oocytes coinjected with the α_{10} and β_2 mRNAs expressed I_{Ba} (108 \pm 39 nA, $n = 4$) that resembled the $\alpha_{10}\alpha_{2b}\beta_2$ -mediated currents,




Figure 5. Autoradiographs of PCR Products Showing Distribution of Voltage-Dependent Ca^{2+} Channel Subunit Transcripts and Alternative Splicing of the α_2 and β Transcripts

IMR32 cytoplasmic RNA and human primary tissue poly(A)⁺ RNAs were used as templates to synthesize cDNA prior to PCR analysis.

(A and B) PCR products of pHBCaCH α_2 , a human brain α_2 cDNA clone (lane 1), IMR32 cells (lane 2), hippocampus and basal ganglia (lane 3), habenula (lane 4), thalamus (lane 5), aorta (lane 6), skeletal muscle (lane 7), and p2.15Δ5', a rabbit skeletal muscle α_2 clone (lane 8), were hybridized with (A) an α_2 oligonucleotide (nucleotides 1597–1619 corresponding to Pro-507 to Thr-514; Ellis et al., 1988) or (B) an α_2 oligonucleotide (nucleotides 1876–1896 corresponding to Lys-602 to Asp-608). The PCR reactions were primed with human α_2 oligonucleotides, nucleotides 1455–1479, and the complement of nucleotides 1931–1955. An approximately equal mass of DNA was present in each lane. The sizes of the 490 bp, 501 bp, and 540 bp α_2 -specific PCR products derived from human aorta, IMR32 cell and CNS tissues, and skeletal muscle RNAs, respectively, were further

confirmed by electrophoresis through a 1% agarose/2% NuSieve composite gel. The weaker hybridization of the human α_2 -derived oligonucleotide with the 490 bp aorta and 540 bp skeletal muscle PCR products further supports their difference from the α_2 transcript. Each band observed also hybridized with an α_2 tissue nonspecific probe, nucleotides 1601–1626 (data not shown).

(C) PCR products of pHBCaCH β_1 , a human brain β_1 cDNA clone (lane 1), IMR32 cells (lane 2), hippocampus and basal ganglia (lane 3), habenula (lane 4), thalamus (lane 5), skeletal muscle (lane 6), aorta (lane 7), and pRSMCaCH β_2 , a rabbit skeletal muscle β_2 cDNA clone (lane 8), were hybridized with a β_2 oligonucleotide, nucleotides 753–784. The PCR products were primed with β_2 oligonucleotides, nucleotides 541–560, and the complement of nucleotides 953–972.

(D) PCR products of pVCCIII(A), an α_2 cDNA clone (lane 1), human genomic DNA (lane 2), IMR32 cells (lane 3), skeletal muscle (lane 4), hippocampus and basal ganglia (lane 5), habenula (lane 6), and thalamus (lane 7), were hybridized with an α_2 oligonucleotide, nucleotides 164–187. The PCR products were primed with α_2 oligonucleotides, nucleotides –39 to –18, and the complement of nucleotides 201–314.




Figure 6. Functional Expression of α_{1D} , α_{2B} , and β_1 in Xenopus Oocytes

(A) I_{Ca} recorded before and after application of Bay K 8644 (1 μM) in an oocyte injected with α_{1D} , α_{2B} , and β_1 mRNAs. Test pulse, –10 mV; holding potential, –50 mV.

(B) Peak current-voltage relations before (open circles) and after (closed circles) application of Bay K 8644 for the α_{1D} , α_{2B} , and β_1 mRNA-injected cell of (A). Holding potential, –50 mV.

(C) Currents before and after (+) application of nifedipine (5 μM) in an oocyte injected with α_{1D} , α_{2B} , and β_1 mRNAs. Current traces are signal averages of three traces before and three traces after application of nifedipine. Test pulse, 0 mV; holding potential, –50 mV.

(D) Currents in the absence and presence (+) of ω -CgTx (10 μM) in an oocyte injected with α_{1D} , α_{2B} , and β_1 mRNAs. Bay K 8644 (1 μM) was present throughout. Current traces are signal averages of three traces before and three traces after application of ω -CgTx for approximately 1.5 min. Test pulse, 0 mV; holding potential, –50 mV.

(E) Currents before and after application of Bay K 8644 (1 μM) in an oocyte injected with α_{2B} and β_1 mRNAs. Superimposed current traces are signal averages of four traces before and four traces after application of Bay K 8644. Test pulse, 20 mV; holding potential, –90 mV.

(F) Peak current-voltage relation for the α_{2B} and β_1 mRNA-injected cell of (E). Holding potential, –90 mV.

although the magnitude of the current was, on average, smaller. Two of four oocytes injected with $\alpha_{10}\beta_2$ responded to Bay K 8644 application similarly to the $\alpha_{10}\alpha_{2b}\beta_2$ -mediated currents, whereas the remaining two showed no response. Three of five oocytes coinjected with the α_{10} and α_{2b} mRNAs displayed very small currents (15–30 nA) and were unresponsive to Bay K 8644.

To ensure that the currents observed in the $\alpha_{10}\alpha_{2b}\beta_2$ -injected oocytes were mediated by the α_{10} subunit, expression of the β_2 or α_{2b} subunits alone or both together was assayed. Oocytes injected with the α_{2b} mRNA displayed no detectable I_{Ba} ($n = 5$). Surprisingly, oocytes injected with β_2 mRNA displayed I_{Ba} upon depolarization (54 ± 23 nA, $n = 5$), and $\alpha_{2b}\beta_2$ -injected oocytes displayed I_{Ba} (Figure 6E) approximately 50% larger than the I_{Ba} of β_2 -injected oocytes (81 ± 60 nA, $n = 21$). Oocytes injected with the β_2 mRNA or the α_{2b} and β_2 mRNAs together displayed I_{Ba} that typically was observed first at -30 mV and that peaked at -10 – -20 mV (Figure 6F). Macroscopically, the β_2 - and $\alpha_{2b}\beta_2$ -induced currents were indistinguishable.

In contrast to the $\alpha_{10}\alpha_{2b}\beta_2$ -mediated currents, the β_2 and $\alpha_{2b}\beta_2$ currents showed both a significant inactivation during the test pulse and a strong sensitivity to the holding potential. The I_{Ba} observed in oocytes coinjected with α_{2b} and β_2 mRNAs usually inactivated markedly during a 140 ms pulse (Figure 6E). Changing the holding potential of oocytes coinjected with the α_{2b} and β_2 mRNAs from -90 mV to -50 mV reduced the I_{Ba} $81\% \pm 15\%$ ($n = 11$). In contrast, I_{Ba} measured in oocytes coinjected with the $\alpha_{10}\alpha_{2b}\beta_2$ mRNAs was reduced $24\% \pm 16\%$ ($n = 11$) when the holding potential was changed from -90 mV to -50 mV.

The $\alpha_{2b}\beta_2$ -mediated I_{Ba} was also pharmacologically distinct from the $\alpha_{10}\alpha_{2b}\beta_2$ -mediated current. Oocytes coinjected with α_{2b} and β_2 mRNAs displayed I_{Ba} that was insensitive to Bay K 8644 ($n = 11$; Figure 6E). Nifedipine sensitivity was difficult to measure because of the holding potential sensitivity of both nifedipine and the $\alpha_{2b}\beta_2$ -mediated I_{Ba} . Nevertheless, two oocytes coinjected with the α_{2b} and β_2 mRNAs displayed measurable I_{Ba} (25–45 nA) when depolarized from a holding potential of -50 mV, and these currents were insensitive to nifedipine (5–10 μ M) application. The $\alpha_{2b}\beta_2$ -mediated I_{Ba} showed a sensitivity to heavy metals similar to the $\alpha_{10}\alpha_{2b}\beta_2$ -mediated current.

Discussion

Distinct Neuronal Ca^{2+} Channel Subunits Comprise a Novel DHP-Sensitive Subtype

Our results demonstrate that the α_{10} subunit mediates DHP-sensitive, high voltage-activated, long-lasting Ca^{2+} channel activity (Figure 6A). Significant functional expression in oocytes of the α_{10} subunit is dependent on the coexpression of the β_2 subunit and is enhanced by coexpression with the α_{2b} subunit. The biophysical properties of activation and inactivation kinetics and voltage sensitivity of the channel formed

by the α_{10} , α_{2b} , and β_2 subunits are generally consistent with previous characterizations of neuronal L-type Ca^{2+} channels (Bean, 1989; Hess, 1990; Swandulla et al., 1991).

Immunoprecipitation of a neuronal DHP receptor previously has revealed the presence of an α_1 , α_2 , and β subunit complex (Ahlijanian et al., 1990). As an initial step toward a detailed characterization of the multiple subtypes of neuronal voltage-dependent Ca^{2+} channels, we cloned and expressed the human neuronal α_{10} , α_{2b} , and β_2 subunits. Characterization of these clones revealed that both the α_{10} and β transcripts expressed in neuronal tissue are differentially processed. Alternatively spliced α_{10} transcripts involve at least four regions: the IS6 region reported here, the cytoplasmic loop between IS6 and IS1 (Hui et al., 1991; data not shown), the IVS3 region, and the extracellular loop between the IVS3 and IVS4 regions (Pérez-Reyes et al., 1990). In addition, a recent report described a possible form of α_{10} with a truncated carboxyl terminus, although the functional significance of this form is unknown (Hui et al., 1991). Minimally, three forms of the α_2 subunit exist (Figures 5A and 5B): α_{2a} , expressed in skeletal muscle (Ellis et al., 1988); α_{2b} , expressed in neuronal tissues; and α_{2c} , expressed in aorta. At least four forms of the β subunit also exist: β_1 , expressed in skeletal muscle; β_2 and β_3 , expressed in human brain tissue; and β_4 , detected in aorta (Figure 5C). Additional forms of the β subunit may also be expressed, as indicated by two β -specific transcripts identified in skeletal muscle (Ruth et al., 1989).

Recently, a rabbit brain α_1 subunit, designated BI, was cloned and expressed (Mori et al., 1991). Not only does this subunit differ structurally from the α_{10} subunit (Figure 2), but the biophysical and pharmacological properties of the Ca^{2+} channel, formed by coexpression of the BI subunit with the rabbit skeletal muscle α_2 and β_1 subunits, differ from those of the human neuronal $\alpha_{10}\alpha_{2b}\beta_2$ recombinant channel. The BI-mediated Ca^{2+} channel activity is insensitive to both DHPs and ω -CgTx and inactivates rapidly compared with the α_{10} -mediated activity. The expression in *Xenopus* oocytes of both the BI-mediated and α_{10} -mediated I_{Ba} requires the coexpression of a β subunit. Thus, two structurally and pharmacologically distinct α_1 subunits expressed in neuronal tissues require a β subunit for functional Ca^{2+} channel activity in oocytes, in contrast to the α_1 subunits expressed in cardiac (Mikami et al., 1989) and smooth muscle (Biel et al., 1990).

The α_1 subunits expressed in both cardiac and lung tissues are likely encoded by the same gene (Biel et al., 1990). This gene encodes mRNAs that direct the synthesis of DHP-sensitive Ca^{2+} channels in *Xenopus* oocytes with macroscopic biophysical properties similar to the $\alpha_{10}\alpha_{2b}\beta_2$ channel (Mikami et al., 1989; Biel et al., 1990). However, the human neuronal $\alpha_{10}\alpha_{2b}\beta_2$ DHP-sensitive channel has a current-voltage relation that is shifted by approximately -20 mV, and its tail currents are markedly prolonged after Bay K 8644 application compared with the cardiac and lung channel

types. A comparison of the single-channel properties might further distinguish these different DHP-sensitive L-type Ca^{2+} channels.

The β_2 Subunit Stimulates DHP-Insensitive I_{Ba} in *Xenopus* Oocytes

Our results suggest that the α_2 and β subunits expressed in skeletal muscle ($\alpha_{2\text{s}}$ and β_1) differ structurally (Figure 3; Figure 4; Figure 5) and possibly functionally from the α_2 and β subunits expressed in brain tissue ($\alpha_{2\text{b}}$ and β_2). *Xenopus* oocytes coinjected with the rabbit skeletal muscle $\alpha_{2\text{s}}$ and β_1 mRNAs apparently do not display I_{Ba} upon depolarization (Mori et al., 1991). This is in contrast to our observation that oocytes injected with the human neuronal β_2 mRNA alone or coinjected with the β_2 and $\alpha_{2\text{b}}$ mRNAs display significant I_{Ba} upon depolarization. Coexpression of the $\alpha_{2\text{b}}$ subunit enhances the I_{Ba} , but $\alpha_{2\text{b}}$ mRNA shows no activity when injected alone.

The Ca^{2+} channel expressed in $\alpha_{2\text{b}}\beta_2$ -injected oocytes has pharmacological and biophysical properties that resemble *Xenopus* oocyte endogenous voltage-dependent Ca^{2+} channels (Dascal et al., 1986). Similar to the skeletal muscle β_1 subunit (Ruth et al., 1989), the β_2 subunit lacks hydrophobic segments capable of forming transmembrane domains. Thus, it is unlikely that the β_2 subunit alone is forming an ion channel. It is more probable that a homologous α_1 subunit exists in oocytes comprising an endogenous Ca^{2+} channel and that the activity mediated by this α_1 subunit is enhanced by the expression of the β_2 subunit, similar to that observed for the $\alpha_{1\text{D}}$ and BI activities. Further information concerning the structure of the endogenous *Xenopus* oocyte Ca^{2+} channel is not yet available.

The Ca^{2+} channel stimulated by the presence of the β_2 subunit may contribute an inactivating, DHP-insensitive component of I_{Ba} to the total current in $\alpha_{1\text{D}}\alpha_{2\text{b}}\beta_2$ -injected oocytes, especially when recorded from strongly negative holding potentials. Recordings made from $\alpha_{1\text{D}}\alpha_{2\text{b}}\beta_2$ -injected oocytes at different holding potentials support this possibility and indicate that such contamination can be reduced, though not necessarily eliminated, by holding at -50 mV. The DHP-insensitive β_2 -mediated current may account for the residual inactivating I_{Ba} detected in $\alpha_{1\text{D}}\alpha_{2\text{b}}\beta_2$ -injected oocytes in the presence of nifedipine (Figure 6C).

ω -CgTx Interacts with the Neuronal DHP-Sensitive Ca^{2+} Channel

ω -CgTx blocks neuronal N-type Ca^{2+} channels irreversibly (Feldman et al., 1987; McCleskey et al., 1987). In contrast to this high affinity block, ω -CgTx blocks the $\alpha_{1\text{D}}\alpha_{2\text{b}}\beta_2$ channel reversibly with an affinity probably in the micromolar range, as indicated by the partial block with 10 – 15 μM ω -CgTx. Although preliminary experiments indicate that the $\alpha_{2\text{b}}\beta_2$ -mediated channel may be inhibited by ω -CgTx, block of Bay K 8644-induced tail currents in $\alpha_{1\text{D}}\alpha_{2\text{b}}\beta_2$ -injected oocytes demonstrates that ω -CgTx also interacts with the

DHP-sensitive $\alpha_{1\text{D}}\alpha_{2\text{b}}\beta_2$ channel. Reversible block by ω -CgTx of L-type (Aosaki and Kasai, 1989), T-type (McCleskey et al., 1987), and a subclass of N-type (Plummer et al., 1989) Ca^{2+} channels has been reported. Furthermore, Ca^{2+} -dependent ATP release from elasmobranch electroplax synaptosomes is blocked reversibly by ω -CgTx with micromolar affinity (Yeager et al., 1987). It thus appears that variable affinity for ω -CgTx may be shared by several types of voltage-dependent Ca^{2+} channels. A weak block such as we have demonstrated for the $\alpha_{1\text{D}}\alpha_{2\text{b}}\beta_2$ L-type channel may account for the conflicting results reported in the literature concerning the ability of ω -CgTx to block neuronal L-type channels (McCleskey et al., 1987; Suzuki and Yoshioka, 1987; Aosaki and Kasai, 1989; Plummer et al., 1989).

Conclusion

The function of DHP-sensitive Ca^{2+} channels in skeletal and cardiac muscle has been extensively studied (Hess, 1990). In contrast, the role of the neuronal L-type Ca^{2+} channel is poorly understood (Miller, 1987). L-type Ca^{2+} channels may mediate the release of neurotransmitters from some types of neurons (Holz et al., 1988). However, functional analysis is difficult due to the mixed population of voltage-dependent Ca^{2+} channel subtypes in continuous cell lines as well as cells in primary tissues. For example, L-type Ca^{2+} channels contribute a minor fraction of the I_{Ba} detectable in the cell bodies of IMR32 cells (Carbone et al., 1990; unpublished data), PC12 cells (Plummer et al., 1989), certain sensory neurons (Aosaki and Kasai, 1989), and sympathetic neurons (Plummer et al., 1989; Jones and Jacobs, 1990). In contrast, L-type channels contribute substantial I_{Ba} in some populations of sensory neurons (Scroggs and Fox, 1991) and certain CNS neurons (Mogul and Fox, 1991; Regan et al., 1991).

Our characterization of a novel human neuronal voltage-dependent Ca^{2+} channel firmly establishes the existence of multiple subtypes of DHP-sensitive L-type Ca^{2+} channels. Furthermore, this human neuronal Ca^{2+} channel appears to have functional and pharmacological properties distinct from any other recombinant Ca^{2+} channel expressed to date. Together with the evidence for differentially processed mRNAs encoding three subunits of voltage-dependent Ca^{2+} channels, these results indicate that the molecular diversity of this ion channel class is much greater than previously proposed by traditional biophysical and pharmacological studies.

Experimental Procedures

Nomenclature

The following nomenclature is used for the α_1 gene family and the differentially processed α_1 and β transcripts. The structurally distinct human neuronal α_1 gene product described here is designated $\alpha_{2\text{b}}$ in accordance with its 96.3% deduced amino acid sequence identity to the rat brain class D sequence (Snutch et al., 1990). The α_2 gene product expressed in skeletal muscle is designated $\alpha_{2\text{s}}$; the differentially processed α_2 transcript expressed in neuronal tissues is designated $\alpha_{2\text{b}}$; the aorta α_2 tran-

script is designated α_2 . The β gene product expressed in skeletal muscle is designated β_1 ; the β transcript expressed in neuronal tissues is differentially processed to produce β_2 and β_3 transcripts. An additional β transcript expressed in aorta is designated β_4 .

cDNA Libraries

Recombinant cDNA libraries were prepared, and individual cDNA clones were characterized essentially as previously described by Ellis et al. (1988). Unless otherwise noted, the nucleotide numbers in the text refer to cDNA coding sequence. For the isolation of human neuronal α_{10} subunit cDNAs, RNA was isolated from the human neuroblastoma IMR32 cell line (ATCC #CCL127), which had been grown in 1.0 mM dibutyl cAMP for 10 days. Four different cDNA libraries were constructed into the phage vector λ gt11: oligo(dT)-primed double-stranded cDNA, 1–3 kb size fractionated by agarose gel electrophoresis; oligo(dT)-primed double-stranded cDNA, 3–9 kb size fractionated; random-primed double-stranded cDNA, >1.8 kb; and specifically primed (nucleotides 2417–2446 of α_{10}) double-stranded cDNA, >1.5 kb. Human neuronal α_{10} subunit cDNAs were isolated from a human basal ganglia cDNA library (ATCC #37433) and a human brain stem cDNA library (ATCC #37432). Human brain β_2 and β_3 subunit cDNAs were isolated from a human hippocampus cDNA library constructed in the λ phage vector λ ZAPII (Stratagene, La Jolla, CA, #936205).

Isolation of Recombinant cDNAs Encoding Different Ca^{2+} Channel Subunits

α_{10} Subunit

Approximately 1×10^6 recombinants of the 1–3 kb library were screened with the rabbit skeletal muscle α_1 subunit cDNA (Ellis et al., 1988). Clone $\lambda\alpha 1.36$ (nucleotides 2347–3771 of α_{10}) was isolated and characterized, and the insert was used to screen the 3–9 kb library. Clone $\lambda\alpha 1.80$ (nucleotides 1573–5958) was isolated and characterized, and the 3' portion of the insert was used to screen the random-primed library from which clone $\lambda\alpha 1.163$ (nucleotides 4690–7125) was isolated. The 5' portion of $\alpha 1.80$ was subsequently used to screen the random-primed library, resulting in the isolation of clone $\lambda\alpha 1.144$ (nucleotides –510 to 1921). The 5' portion of $\alpha 1.80$ was then used to screen the specifically primed library from which clone $\lambda\alpha 1.136$ (nucleotides 1117–2478) was isolated.

α_2 Subunit

Human genomic α_2 clones were isolated to use as α_2 -specific probes of human neuronal cDNA libraries. A rabbit skeletal muscle α_2 cDNA fragment, clone SkMCaCHa2.2, comprising nucleotides 43–272 (Ellis et al., 1988), was used to identify and clone two α_2 -specific, human genomic EcoRI fragments, HGCaCHa2.20 (3.5 kb) and HGCaCHa2.9 (3.0 kb). Restriction mapping and DNA sequencing revealed that HGCaCHa2.20 contains an 82 bp exon (nucleotides 96–177 of the human α_2 coding sequence) and that HGCaCHa2.9 contains 105 bp of an exon (nucleotides 178–282 of the coding sequence). These restriction fragments were used to screen the human basal ganglia cDNA library. HBCaCHa2.1 was isolated (nucleotides –6 to 1129) and used to screen the human brain stem cDNA library. Two clones were isolated, HBCaCHa2.5 (nucleotides –34 to 1128) and HBCaCHa2.8 (nucleotides 680–1528 followed by 1600 nucleotides of intervening sequence). HBCaCHa2.8 was used to rescreen the brain stem library and to isolate HBCaCHa2.11 (nucleotides 845–3566).

β_1 and β_2 Subunits

A rabbit skeletal muscle β_1 subunit cDNA fragment (Ellis et al., 1988; Ruth et al., 1989) was used to screen the human hippocampus cDNA library. Two clones, $\lambda\beta 1$ and $\lambda\beta 4$, were isolated that appear to encode alternative splice products of the human β subunit transcript expressed in the brain, β_2 and β_3 , respectively. $\lambda\beta 1$ begins at nucleotides 69 and extends 107 nucleotides beyond the translation stop codon, encoding 1367 nucleotides of coding sequence. $\lambda\beta 1$ also contains a 448 nucleotide intron between nucleotides 1146 and 1147 of the coding sequence. $\lambda\beta 4$ begins at nucleotide 246 of the coding sequence and diverges from β_2 at nucleotide 1333 as described in the Results. $\lambda\beta 1$ was used to

rescreen the hippocampus cDNA library from which clone $\lambda\beta 1.18$ was isolated, characterized, and determined to encode nucleotides 1–325 of the β_2 coding sequence.

PCR Analysis

PCR analyses were performed essentially as described by Innis et al. (1990). IMR32 cell cytoplasmic RNA was prepared as described by Ausubel et al. (1988). For the analysis of the series of 5' methionine codons in the α_{10} cDNA, four oligonucleotide primers were synthesized (numbered in the 5' to 3' orientation): (1) nucleotides –39 to –18, beginning 39 nucleotides 5' of the first methionine codon; (2) nucleotides 58–81; (3) nucleotides 164–187; and (4) nucleotides 314–291. The oligonucleotide pairs (1, 4), (2, 4), and (3, 4) were used to prime PCR assays of cytoplasmic RNA and human genomic DNA. PCR amplification of human genomic DNA and IMR32 cytoplasmic RNA with oligonucleotide pairs (2, 4) and (3, 4) gave the predicted size product (260 and 150 bp, respectively). The cytoplasmic RNA assayed with the pair (1, 4) gave the predicted size product (350 bp); a PCR product of genomic DNA primed with the pair (1, 4) was not detected. The lack of a PCR product primed with pair (1, 4) on genomic DNA suggested the possible presence of an intron between oligonucleotides 1 and 2 and indicated that the positive results with the RNAs could not be due to genomic DNA contamination of the RNA preparations. The cytoplasmic RNA PCR product of the (1, 4) oligonucleotide pair was cloned and sequenced.

Construction of Full-Length cDNAs

α_{10} Subunit

pVDCIII(A) was constructed using $\alpha 1.144$ (nucleotides –184 to 1222), $\alpha 1.136$ (nucleotides 1222–2157), $\alpha 1.80$ (nucleotides 2157–4784), and $\alpha 1.163$ (nucleotides 4784–7125). PCR analysis of the α_{10} transcript revealed that $\alpha 1.80$ contained a 148 nucleotide deletion (nucleotides 2474–2621). To correct this deletion, PCR was performed on IMR32 RNA, and the AccI–BgIII fragment (nucleotides 2254–3380) was isolated and used to replace the $\alpha 1.80$ fragment.

α_2 Subunit

pHBCaCHa2(A) was constructed using HBCaCHa2.5 (nucleotides –34 to 1027) and HBCaCHa2.11 (nucleotides 1027–3566).

β_2 Subunit

To construct pHBCaCHa2 β_2 -RBS(A), the 448 nucleotide intron of $\lambda\beta 1$ first was deleted via site-directed mutagenesis (Sambrook et al., 1989). $\lambda\beta 1$ was subcloned into M13mp19. The mutagenic oligonucleotide was the sense strand of β_2 encoding nucleotides 1128–1165. The final construct was designated $\beta\beta 1(-)$. pHBCaCHa2 β_2 -RBS(A) then was constructed using $\lambda\beta 1.18$ (nucleotides 1–282) and $\beta\beta 1(-)$ (nucleotides 282–1547). The 5' untranslated sequence in $\lambda\beta 1.18$ was replaced with an efficient ribosomal-binding site so that the sequence reads 5'-GAATTC (EcoRI) ACCACC (ribosomal-binding site) ATG (start codon) ... -3'. Each α_{10} , α_2 , and β_2 full-length construct was subcloned into pCDNA1 (Invitrogen, San Diego, CA).

Expression Studies in *Xenopus* Oocytes

In vitro transcripts of human neuronal α_{10} , α_2 , and β_2 subunit cDNAs were synthesized according to the instructions of the mCAP mRNA Capping Kit (Stratagene, La Jolla, CA, #200350). Each plasmid first was linearized by restriction digestion: pVDCIII(A) with XhoI, pHBCaCHa2(A) with XhoI, and pHBCaCHa2 β_2 -RBS(A) with EcoRV. T7 RNA polymerase was used to transcribe each cDNA. *Xenopus laevis* oocytes were dissociated and defolliculated by collagenase treatment and maintained in 100 mM NaCl, 2 mM KCl, 1.0 mM CaCl_2 , 1 mM MgCl_2 , 5 mM HEPES (pH 7.6), 20 $\mu\text{g}/\text{ml}$ ampicillin, and 25 $\mu\text{g}/\text{ml}$ streptomycin at 19°C–25°C for 2–5 days after injection and prior to recording. Oocytes were injected with 6 ng of each in vitro synthesized mRNA species per cell in a volume of 50 nl and were assayed by the two-electrode voltage-clamp method (Dascal, 1987) using the pClamp (Axon Instruments) software package in conjunction with a Labmaster 125 kHz data acquisition interface (Scientific Solutions) to generate voltage commands and to acquire and analyze data. Current signals were digitized at 1–5 kHz and filtered appropriately. I_h

was recorded in a solution intended to minimize currents carried through K^+ , Cl^- , or Na^+ channels (Snutch et al., 1990): 40 mM $BaCl_2$, 36 mM tetraethylammonium chloride, 2 mM KCl, 5 mM 4-aminopyridine, 0.15 mM niflumic acid, 5 mM HEPES (pH 7.6). Currents were leak subtracted by the P/n method provided in pClamp, where n was -4 or -6. Drugs were applied directly into the 60 μ l bath while the perfusion pump was turned off. Bay K 8644 and nifedipine were prepared fresh from stock solutions (in dimethyl sulfoxide) and diluted into the bath solution. The dimethyl sulfoxide concentration of the final drug solutions in contact with the cell never exceeded 0.1%. Control experiments showed that 0.1% dimethyl sulfoxide had no effect on membrane currents. ω -CgTx was prepared in a 15 mM $BaCl_2$ bath solution plus 0.1% cytochrome C (Sigma) (Feldman et al., 1987) to serve as a carrier protein. Control experiments showed that cytochrome C had no effect on currents. Before and during ω -CgTx application, test pulses were recorded at 20 s intervals from the holding potential (-90 mV or -50 mV) to the peak I_{Ca} (-10 mV to 10 mV). To reduce the inhibition of ω -CgTx binding by divalent cations (McCleskey et al., 1987), recordings were made in 15 mM $BaCl_2$, 73.5 mM tetraethylammonium chloride, and the remaining ingredients identical to the 40 mM Ba^{2+} recording solution.

Acknowledgments

We thank Michelle Hendricks for skillful technical assistance. We also thank Paul Brust, Vincent Dionne, Jean Ellis, Ronald Evans, Stephen Heinemann, William Raschke, and Paula Schoenck for helpful discussions regarding this work and manuscript.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC Section 1734 solely to indicate this fact.

Received September 11, 1991; revised October 23, 1991.

References

- Ahijanian, M. K., Westenbroek, R. E., and Catterall, W. A. (1990). Subunit structure and localization of dihydropyridine-sensitive calcium channels in mammalian brain, spinal cord, and retina. *Neuron* 4, 819-832.
- Aosaki, T., and Kasai, H. (1989). Characterization of two kinds of high-voltage-activated Ca-channel currents in chick sensory neurons. *Pflügers Arch.* 414, 150-156.
- Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. C., Smith, J. A., and Struhl, K. (1988). Preparation and analysis of RNA. In *Current Protocols in Molecular Biology* (New York: John Wiley & Sons), pp. 4.1.4.
- Bause, E. (1983). Structural requirements of N-glycosylation of proteins. Studies with proline peptides as conformational probes. *Biochem. J.* 209, 331-336.
- Bean, B. P. (1984). Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. *Proc. Natl. Acad. Sci. USA* 81, 6388-6392.
- Bean, B. P. (1989). Classes of calcium channels in vertebrate cells. *Annu. Rev. Physiol.* 51, 367-384.
- Biel, M., Ruth, P., Bosse, E., Huilln, R., Stühmer, W., Flockerzi, V., and Hofmann, F. (1990). Primary structure and functional expression of a high voltage activated calcium channel from rabbit lung. *FEBS Lett.* 269, 409-412.
- Campbell, K. P., Leung, A. T., and Sharp, A. H. (1988). The biochemistry and molecular biology of the dihydropyridine-sensitive calcium channel. *Trends Neurosci.* 11, 425-430.
- Carbone, E., Sher, E., and Clementi, F. (1990). Ca currents in human neuroblastoma IMR32 cells: kinetics, permeability and pharmacology. *Pflügers Arch.* 416, 170-179.
- Dascal, N. (1987). The use of *Xenopus* oocytes for the study of ion channels. *CRC Crit. Rev. Biochem.* 22, 317-387.
- Dascal, N., Snutch, T. P., Lübbert, H., Davidson, N., and Lester, H. A. (1986). Expression and modulation of voltage-gated calcium channels after RNA injection in *Xenopus* oocytes. *Science* 231, 1147-1150.
- Ellis, S. B., Williams, M. E., Ways, N. R., Brenner, R., Sharp, A. H., Leung, A. T., Campbell, K. P., McKenna, E., Koch, W. J., Hui, A., Schwartz, A., and Harpold, M. M. (1988). Sequence and expression of mRNAs encoding the α_1 and α_2 subunits of a DHP-sensitive calcium channel. *Science* 241, 1661-1664.
- Feldman, D. H., Olivera, B. M., and Yoshikami, D. (1987). Omega Conus geographus toxin: a peptide that blocks calcium channels. *FEBS Lett.* 214, 295-300.
- Fox, A. P., Nowycky, M. C., and Tsien, R. W. (1987). Kinetic and pharmacological properties distinguishing three types of calcium currents in chick sensory neurones. *J. Physiol.* 394, 149-172.
- Glass, D. B., El-Maghrabi, M. R., and Pilch, S. J. (1986). Synthetic peptides corresponding to the site phosphorylated in 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as substrates of cyclic nucleotide-dependent protein kinases. *J. Biol. Chem.* 261, 2987-2993.
- Hess, P. (1990). Calcium channels in vertebrate cells. *Annu. Rev. Neurosci.* 13, 337-356.
- Holz, G. G., Dunlap, K., and Kream, R. M. (1988). Characterization of the electrically evoked release of substance P from dorsal root ganglion neurons: methods and dihydropyridine sensitivity. *J. Neurosci.* 8, 463-471.
- Hui, A., Ellinor, P. T., Krizanov, O., Wang, J.-J., Diebold, R. J., and Schwartz, A. (1991). Molecular cloning of multiple subtypes of a novel rat brain isoform of the α_1 subunit of the voltage-dependent calcium channel. *Neuron* 7, 35-44.
- Innis, M. A., Gelfand, D. H., Sninsky, J. J., and White, T. J. (1990). *PCR Protocols: A Guide to Methods and Applications* (San Diego, California: Academic Press), pp. 3-27.
- Jay, S. D., Ellis, S. B., McCue, A. F., Williams, M. E., Vedvick, T. S., Harpold, M. M., and Campbell, K. P. (1990). Primary structure of the γ subunit of the DHP-sensitive calcium channel from skeletal muscle. *Science* 248, 490-492.
- Jay, S. D., Sharp, A. H., Kahl, S. D., Vedvick, T. S., Harpold, M. M., and Campbell, K. P. (1991). Structural characterization of the dihydropyridine-sensitive calcium channel α_2 -subunit and the associated δ peptides. *J. Biol. Chem.* 266, 3287-3293.
- Jones, S. W., and Jacobs, L. S. (1990). Dihydropyridine actions on calcium currents of frog sympathetic neurons. *J. Neurosci.* 10, 2261-2267.
- Koch, W. J., Ellinor, P. T., and Schwartz, A. (1990). cDNA cloning of a dihydropyridine-sensitive calcium channel from rat aorta. *J. Biol. Chem.* 265, 17786-17791.
- Kozak, M. (1987). An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. *Nucl. Acids Res.* 15, 8125-8132.
- Llinás, R., Sugimori, M., Lin, J. W., and Cherksey, B. (1989). Blocking and isolation of a calcium channel from neurons in mammals and cephalopods utilizing a toxin fraction (FTX) from funnel-web spider poison. *Proc. Natl. Acad. Sci. USA* 86, 1689-1693.
- McCleskey, E. W., Fox, A. P., Feldman, D. H., Cruz, L. J., Olivera, B. M., Tsien, R. W., and Yoshikami, D. (1987). ω -Conotoxin: direct and persistent blockade of specific types of calcium channels in neurons but not muscle. *Proc. Natl. Acad. Sci. USA* 84, 4327-4331.
- Mikami, A., Imoto, K., Tanabe, T., Nildome, T., Mori, Y., Takeshima, H., Narumiya, S., and Numa, S. (1989). Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. *Nature* 340, 230-233.
- Miller, R. J. (1987). Multiple calcium channels and neuronal function. *Science* 235, 46-52.
- Mogul, D. J., and Fox, A. P. (1991). Evidence for multiple types of Ca^{2+} channels in acutely isolated hippocampal CA3 neurones of the guinea-pig. *J. Physiol.* 433, 259-281.
- Mori, Y., Friedrich, T., Kim, M.-S., Mikami, A., Nakai, J., Ruth, P.,

- Bosse, E., Hofmann, F., Flockerzi, V., Furuichi, T., Mikoshiba, K., Imoto, K., Tanabe, T., and Numa, S. (1991). Primary structure and functional expression from complementary DNA of a brain calcium channel. *Nature* 350, 398-402.
- Numa, N., and Noda, M. (1986). Molecular structure of sodium channels. *Ann. NY Acad. Sci.* 479, 338-355.
- Perez-Reyes, E., Kim, H. S., Lacerda, A. E., Horne, W., Wei, X., Rampe, D., Campbell, K. P., Brown, A. M., and Birnbaumer, L. (1989). Induction of calcium currents by the expression of the α_1 -subunit of the dihydropyridine receptor from skeletal muscle. *Nature* 340, 233-236.
- Perez-Reyes, E., Wei, X., Castellano, A., and Birnbaumer, L. (1990). Molecular diversity of L-type calcium channels. *J. Biol. Chem.* 265, 20430-20436.
- Pumner, M. R., Logothetis, D. E., and Hess, P. (1989). Elementary properties and pharmacological sensitivities of calcium channels in mammalian peripheral neurons. *Neuron* 2, 1453-1463.
- Regan, L. J., Sah, D. W. Y., and Bean, B. P. (1991). Ca^{2+} channels in rat central and peripheral neurons: high-threshold current resistant to dihydropyridine blockers and ω -conotoxin. *Neuron* 6, 269-280.
- Regulla, S., Schneider, T., Nastalnczyk, W., Meyer, H. E., and Hofmann, F. (1991). Identification of the site of interaction of the dihydropyridine channel blockers nitrendipine and azidopine with the calcium-channel α_1 subunit. *EMBO J.* 10, 45-49.
- Ruth, P., Röhrkasten, A., Biel, M., Bosse, E., Regulla, S., Meyer, H. E., Flockerzi, V., and Hofmann, F. (1989). Primary structure of the β subunit of the DHP-sensitive calcium channel from skeletal muscle. *Science* 245, 1115-1118.
- Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory).
- Sanguinetti, M. C., and Kass, R. S. (1984). Voltage-dependent block of calcium channel current in the calf cardiac Purkinje fiber by dihydropyridine calcium channel antagonists. *Circ. Res.* 55, 336-348.
- Scroggs, R. S., and Fox, A. P. (1991). Distribution of dihydropyridine and ω -conotoxin-sensitive calcium currents in acutely isolated rat and frog sensory neuron somata: diameter-dependent L channel expression in frog. *J. Neurosci.* 11, 1334-1346.
- Snutch, T. P., Leonard, J. P., Gilbert, M. M., Lester, H. A., and Davidson, N. (1990). Rat brain expresses a heterogeneous family of calcium channels. *Proc. Natl. Acad. Sci. USA* 87, 3391-3395.
- Suzuki, N., and Yoshioka, T. (1987). Differential blocking action of synthetic ω -conotoxin on components of Ca^{2+} channel current in clonal GH3 cells. *Neurosci. Lett.* 75, 235-239.
- Swandulla, D., Carbone, E., and Lux, H. D. (1991). Do calcium channel classifications account for neuronal calcium channel diversity? *Trends Neurosci.* 14, 46-51.
- Tanabe, T., Takeshima, H., Mikami, A., Flockerzi, V., Takahashi, H., Kangawa, K., Kojima, M., Matsuo, H., Hirose, T., and Numa, S. (1987). Primary structure of the receptor for calcium channel blockers from skeletal muscle. *Nature* 328, 313-318.
- Tanabe, T., Beem, K. G., Powell, J. A., and Numa, S. (1988). Restoration of excitation-contraction coupling and slow calcium current in dysgenic muscle by dihydropyridine receptor complementary DNA. *Nature* 336, 134-139.
- Tsien, R. W., Lipscombe, D., Madison, D. V., Bley, K. R., and Fox, A. P. (1988). Multiple types of neuronal calcium channels and their selective modulation. *Trends Neurosci.* 11, 431-438.
- Woodgett, J. R., Gould, K. L., and Hunter, T. (1986). Substrate specificity of protein kinase C use of synthetic peptides corresponding to physiological sites as probes for substrate recognition requirements. *Eur. J. Biochem.* 161, 177-184.
- Yeager, R., Yoshikami, D., Rivier, J., Cruz, L. J., and Mijlanich, G. P. (1987). Transmitter release from electric organ nerve terminals: blockade by the calcium channel antagonist, omega Conus toxin. *J. Neurosci.* 7, 2390-2396.

GenBank Accession Numbers

The nucleotide sequences of the human α_{1D} , α_{1B} , and β_1 cDNAs will appear in the EMBL, GenBank, and DDBJ nucleotide sequence data bases under the accession numbers M76558 (α_{1D}), M76559 (α_{1B}), and M76560 (β_1).

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.